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RNA interference (RNAi) is receiving increasing attention as a form of gene regulation able to 
temporarily silence gene expression through post transcriptional mechanisms.  RNAi agents have 
shown promise in targeting a range of ailments from cancers to myocardial infarction. However, 
RNAi based therapeutics have not passed the clinical trial stage of development, in part due to lack of 
optimal delivery mechanisms. 
  
One means towards improving delivery is the development of localised and sustained delivery systems 
for the RNAi molecule. Such approaches are important as it has previously been found that systemic 
delivery often leads to off target effects and rapid clearance.  The aim of this project has been to assess 
the utility of an enzymatically degradable polyethylene glycol (PEG) hydrogel as a localised delivery 
vehicle. Enzymatically degradable PEG hydrogels that rely on cellular invasion for their degradation 
might enable the release of entrapped RNAi agents to surrounding cells as well as transfection of 
invading cells. 
 
The cationic polymer poly(ethyleneimine) (PEI), was used as a tool to investigate the PEG hydrogel as 
a localised delivery vehicle. Thus, an initial objective of this study was the establishment and 
characterisation of the PEI/siRNA nanoparticle technology in our group.  siRNA was found to be fully 
complexed at a PEI nitrogen to siRNA phosphate ratios of 5:1 and higher. A 10:1 ratio and higher were 
able to protect the siRNA from RNases present in serum for 7 days with up to 65% of RNA still intact. 
A 40:1 ratio was found to be cytotoxic. A 20:1 ratio was found to be the most effective at gene knock 
down and determined to be optimal. 
 
As there is a relatively limited volume available in the PEG hydrogel system used here for loading with 
PEI/siRNA nanoparticles, a study was conducted to assess the maximum concentration of siRNA at 
which effective nanoparticles could be formed. Somewhat unexpectedly it was found that at a 
concentration of 7.5 µM siRNA, nanoparticles showed a significant 40% reduction in transfection 
efficacy of cells cultured in 2D. This finding for PEI nanoparticles indicating a limitation in the dosage 
attainable in the PEG hydrogel system. 
 
The influence of PEG encapsulation for PEI/siRNA nanoparticles on RNase protection was assessed by 
exposing hydrogels with entrapped nanoparticles to serum RNases. The PEG hydrogel was found to 




protection persisted for up to 5 days. PEI/siRNA nanoparticles were retained after encapsulation 
within PEG hydrogels for up to 7 days whilst siRNA alone was entirely released after 24 hours. It is 
possible that this is a limitation of the system. 
 
A 3D invasion assay was developed to more closely mimic the in vivo scenario where cells could invade 
a PEG hydrogel with entrapped nanoparticles but are not initially exposed to high concentrations of 
nanoparticles prior to hydrogel polymerisation.  The assay involved the formation of dermal 
equivalents (cells entrapped within contracted collagen) that were encapsulated within a PEG 
hydrogel. Cells were observed invading the hydrogel within 1 hour of polymerising and continued to 
do so for up to 7 days. Invading cells were seen to take up the fluorescent siRNA although this uptake 
was scant and challenging to quantify. When commercial cell death siRNA sequence nanoparticles 
were encapsulated, a trend towards higher death levels was observed. 
 
In conclusion, PEI/siRNA nanoparticles and related RNAi based assays have been formally established 
in our laboratory and can be used in the future for other applications. A 3D cell invasion assay was 
developed which more closely mimics the in vivo scenario where hydrogels bearing siRNA are 
polymerised within tissue. The increased RNase protection though relatively slight is important for the 
use of hydrogels as localised delivery depots in an in vivo environment. Potential dose limitations of 
the PEG hydrogel system when using PEI nanoparticles and their apparent very tight encapsulation in 
the PEG hydrogels suggests the need for modifications of both nanoparticles and hydrogels to 
optimise efficacy. Future investigations into scaffold based localised siRNA delivery should be 
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1. Literature Review 
 
1.1 RNA interference (RNAi) 
 
In recent years interest in the use of RNAi as an alternative therapeutic for disease has grown. It offers 
researchers the opportunity to exploit endogenous pathways to combat disease. RNAi involves the 
posttranscriptional gene silencing of a target sequence including those targets previously considered 
“undruggable”1. The silencing of target sequences can take the form of either irreversible cleavage of 
the mRNA strand or the prevention of its translation to protein. 
 
Although originally observed in plants2, RNAi was first fully described in the nematode worm, 
Caenorhabditis elegans, in the late 1990’s by Andrew Fire and Craig Mello3. In their study they 
observed a reduction in endogenous protein production in C. elegans after introducing long double 
stranded RNA molecules.  
 
Since its discovery, RNAi has become increasingly used as a research tool investigating gene function, 
but of at least equal importance is its potential as a new therapeutic approach4. Over the last decade 
the number of RNAi related patents has increased drastically, with nearly 500 patent applications as 
well as issued patents pertaining to the use of one form of RNAi alone annually5, demonstrating the 
potential for RNAi as a therapy. 
 
1.1.1 RNA interference structure and mode of action 
 
The suppression of gene translation is activated by the presence of either endogenous or exogenous 
double-stranded RNA (dsRNA). Micro RNAs (miRNAs) are the body’s endogenous regulators of gene 
expression, and have been found to be important regulatory factors in both animals and plants6. They 
are non-coding strands of 21-24 base pairs in length and have the ability to silence multiple different 
mRNA sequences due to having partial homology with many target sequences. Short hairpin RNAs 
(shRNAs) are in essence exogenous in their origins, however they are synthesised endogenously. They 
are transcribed from plasmid DNA (pDNA) which has been introduced into the cell’s nucleus often via 
a viral vector. Small interfering RNAs (siRNA) are usually synthetically derived double stranded RNA 
sequences of similar length to miRNA which may be introduced into the cells cytoplasm via a vector. 
siRNAs can be synthesized or produced via different methods: chemical synthesis, in vitro 
transcription, enzymatic digestion of double stranded RNA, and finally transfection of a pDNA 
encoding shRNA which are then converted to siRNAs7. Both siRNA and shRNA are designed to have 
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full complementarity with a target mRNA sequence.  A high degree of strand specificity or homology 
can result in the immediate irreversible cleavage of the target mRNA while incomplete homology often 
results in translation repression8.   
 
These differing forms of RNA are also related to each other when their processing in the cell is 
compared. They are all processed in virtually the same way but enter the pathway at different stages 
(Figure 1). miRNA genes are transcribed usually by RNA polymerase-II to form primary miRNA (pri-
miRNA) transcripts containing a stem-loop. The stem-loop is recognised by Drosha, an RNase III like 
enzyme, in the nucleus9,10. Drosha processes the transcript into pre-miRNAs, an approximately 60-70 
nucleotide long stem loop which has 3’ overhangs with hydroxyl-termini and 5’ phosphates9. Pre-RNA 
are then transported out of the nucleus by Exportin-5 where they are cleaved by Dicer into dsRNA to 
become functional miRNA8. The dsRNA is then dissociated by the incorporation of the antisense 
strand, known as the guide strand, into the RNA induced silencing complex (RISC), a multi-protein 
complex including Argonaut 2 (Ago2), which then binds to complementary target mRNA sequences at 
the 3’-unstranslated region (UTR). Ago2 is an RNase that is the catalytic element of the RISC11. 
However, it is often the case that miRNA binding takes place with incomplete homology and therefore 
elicits translation repression whereby the strands lack complementarity at the cleavage site thereby 
blocking the so called “slicer activity” observed during direct cleavage of a target strand12. As such 
miRNA can lead to translational repression, as well as mRNA degradation by deadenylation, decapping 
or exonuclease action and in a very few cases where there is a high degree of complementarity, mRNA 
cleavage by AGO protein13–15.  
 
When plasmids encoding shRNA are introduced into the cell and transcribed, the resulting transcripts 
form stem-loop structures known as pre-shRNAs or pre-miRNA mimics that are transported out of the 
nucleus into the cytoplasm in the same manner as pre-miRNAs. They are then processed by Dicer into 
siRNA which is then further processed into single stranded RNAs (ssRNA) and incorporated into the 
RISC to induce silencing of mRNA target sequances8,16.  The siRNA directs the RISC to the target mRNA 
sequence. Ago2, cleaves the target sequence 10 nucleotides from the 5’ end of the strand17. Once 
cleaved the mRNA sequence is released and the guide strand is free to bind another mRNA. A 
drawback to the use of shRNAs in the clinic is the use of pDNA. pDNA requires nuclear shuttling in 
order to function. This is often achieved with viral vectors which have their own set of associated 
shortcomings which will be briefly discussed later. With the use of DNA there is also a risk of insertional 
mutagenesis which is not a risk associated with RNA present in the cytoplasm. 
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siRNAs can be introduced via multiple methods, how it is introduced to the cell determines at which 
step in the process it enters – either in the nucleus in the form of shRNA as described above or directly 
into the cytoplasm. Delivery of siRNAs directly to the cytoplasm negates the need for nuclear shuttling 
as the siRNA enters the pathway after processing by Dicer and before cleavage by Ago2. 
 
 
Figure 1: RNAi pathway. RNAi pathway illustrating the different points at which the various forms of RNAi oligonucleotide 
enter the pathway to elicit gene silencing. Figure adapted from siRNA Versus miRNA as Therapeutics for Gene Silencing13 and 
RNAi the Natural Way18. 
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1.2 RNA interference: challenges to translation to the clinic 
 
Despite much promise as a therapeutic, one of the major constraining factors to the use of RNAi in a 
clinical setting is its delivery into the cell. Both intracellular as well as physiological obstacles prevent 
the efficient delivery of RNAi molecules and need to be overcome before its use as a therapeutic can 
be fully realised. In order to initiate the RNAi pathway, the RNAi molecule needs to be transported to 
the cytoplasm, to the RNAi machinery so as to induce silencing of the target mRNA. RNAs are 
negatively charged due to their phosphate backbones and as such cannot easily pass through the 
cellular membrane – which is of similar charge – without some form of transport vehicle aiding in its 
delivery19,20. Furthermore, RNA molecules are hydrophilic and too large to readily diffuse through the 
hydrophobic lipid bilayers of the cell membrane21. Moreover upon cellular uptake, RNAi molecules 
need to escape degradation in the endo-lysosome. Therefore, any delivery agent used should aid in 
RNAi agent transport across the cell membrane and in endo-lysosomal escape. When delivering RNAi 
systemically, physiological barriers need to be considered. RNAi molecules are subject to degradation 
by nucleases and it has previously been reported that RNAi molecules have a half-life of less than 1 
hour in serum22. Other concerns also include the possibility for off target effects, rapid clearance from 
circulation and localisation to the liver and kidneys23, the potential of overwhelming the endogenous 
machinery used to process the double stranded RNA24, and inducing an innate immune response25–28. 
As such, much of what is delivered never has an effect on the target site29. The delivery concerns 
mentioned above are very similar for both siRNA and miRNA13. 
 
1.2.1 Delivery methods 
 
A variety of approaches towards achieving gene expression regulation have been utilised. These 
approaches have been designed to overcome some of the aforementioned barriers to RNAi delivery, 
and include the use of biological vectors, RNA modification, high repeated doses of RNA and RNA 
incorporation into nanoparticles. 
 
1.2.1.1 Viral vectors 
 
Viral vectors encoding shRNA have been used for a number years to induce RNAi13 and overcome 
many of the obstacles described above for the delivery of RNAi oligonucleotides. They have 
advantages in that they have the ability to efficiently enter the host cell and integrate into the genome 
which results in prolonged silencing4,30. They are also not prone to degradation, therefore the RNA is 
protected until transcribed. The studies below are examples of some of the successes which have been 
reported using viral vectors but associated dangers are also highlighted.  
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Their utility in identifying therapeutically useful miRNA sequences for myocardial infarctions has 
recently been demonstrated in a mouse model. In a study conducted by Eulalio et al31., a high-
throughput functionalised screening of miRNAs was performed to determine which miRNA sequences, 
if administered, would induce cardiac regeneration in the form of cardiomyocyte proliferation. They 
were able to identify forty miRNA sequences which increased DNA synthesis and cytokines in neonatal 
cardiomyocytes, two of which, hsa-miR-590 and hsa-miR-199a, were selected for further testing. An 
adeno-associated virus (AAV) vector expressing the selected strands was injected into the peri-infarct 
zone of female adult CD1 mice that had undergone permanent left anterior descending coronary 
artery ligation. Echocardiography assessment indicated that the left ventricular ejection fraction,  
fractional shortening, end-systolic anterior wall thickness, as well as other associated parameters were 
significantly maintained compared to controls’ measured over 60 days. Infarct size was also 
significantly reduced (± 15% smaller compared to non-treated controls). 
 
Viral vectors have reached the clinical trial stage for the delivery of siRNA ex vivo32, whereby cells are 
modified and then reintroduced into the patient. In one such pilot study, five patients being treated 
for AIDS-related non-Hodgkin’s lymphoma (NHL) received autologous CD34+ haematopoietic 
progenitor cells (HPC)33. The study aimed to use RNAi based gene therapies to control HIV infection 
and demonstrate persistence for a number of months post treatment. Autologous HPCs were 
transduced with a self-inactivating lentiviral vector which encoded a siRNA that targeted chemokine 
receptor 5 (CCR5). CCR5 is an endogenous chemokine receptor in CD4+ T-cells and is a co-receptor for 
HIV-1 infection but is not an essential component for normal T-cell function, rendering it an ideal anti-
HIV target. After receiving chemotherapy, patients were infused with the transduced cells. Patients 
responded positively to treatment with no short term toxicity concomitant with genetically altered 
cells being reported. They were able to demonstrate siRNA expression in human blood cells for up to 
24 months post treatment, indicating the feasibility of RNAi for treatment of HIV in the future.  
Follow up clinical trials34 using similar methodology reported a similar safety profile and the feasibility 
of treatment was confirmed, however, none of the results achieved could conclude that therapy 
resulted in an improved disease state. The small number of patients enrolled in their clinical trial also 
did not allow for a true demonstration of safety with respect to possible genetic mutations.  
 
However, despite these types of positive outcomes, there are many potential side effects associated 
with viral based delivery including mutagenesis, immunogenicity and the potential for there to be a 
continuous cellular presence of RNAi which in many cases is not desirable35,36. This is indeed the case 
when using vectors such as AAV’s and retrovirus’s. Long term silencing of some mRNA targets is 
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advantageous in certain pathological scenarios including the treatment of HIV, for many other 
diseases however, once a patient has recovered the silencing of a given mRNA sequence is no longer 
required. 
 
Although many positives can be taken from the above studies safety concerns should still be noted. 
The risks associated with using viral vectors are highlighted in a study in which a viral vector was used 
to deliver a transgene. In the study, CD34+ bone marrow cells from five boys with X-linked severe 
combined immunodeficiency were transduced ex vivo using a defective retroviral vector37. Initially it 
was reported that there were no adverse effects due to the treatment.  Later however, it was reported 
that one of the participants suffered adverse effects and developed acute lymphoblastic leukaemia as 
a result of participating in the trial due to an insertional mutagenesis event38.  This finding raises 
concern with approaches such as the one detailed above in the clinical trial on AIDS related NHL.  
 
1.2.1.2 Naked and modified siRNA 
 
Though as detailed above, there are several obstacles facing the successful delivery of naked siRNA, 
there are many studies that have utilised this approach. Included below are studies where naked 
siRNA has been delivered in vivo, where it was either injected systemically or directly into the target 
organ. Some tissues have been found to internalise naked siRNA at a much higher level compared to 
others, these include the eye, central nervous system and lung, making direct delivery possible39. 
Naked siRNA is also considered to have a better safety profile compared to viral vectors as well as 
being more easily produced and therefore scalable.  
 
High doses of unmodified siRNA have been rapidly injected into the blood vessels (described as 
hydrodynamic injection) of mice40–43. Rapid injection of a large volume is said to increase the 
permeability of endothelium and the cell membranes of parenchyma cells44.  
In a study looking at the use of siRNA as a potential treatment for hepatitis, hydrodynamic tail vein 
injection was employed to deliver siRNA against the Fas gene42. Fas is known to be a mediator of 
apoptosis in a broad range of liver diseases and it was postulated that inhibition of Fas would inhibit 
hepatocyte cell death and protect the liver from liver failure and fibrosis45. Using a Cy5-labelled Fas 
sequence they assessed hepatocyte uptake of the siRNA in mice. Twenty four hours post final 
treatment with 3 repeated high dose injections, uptake was assessed by flow cytometry and showed 
88 ± 6% of hepatocytes to have taken up siRNA. Treatment with Fas siRNA led to an eight to tenfold 
reduction in levels of Fas mRNA as well as a reduction in the expression of Fas protein in hepatocytes 
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to almost background levels. The hepatocytes isolated from these mice were also found to be resistant 
to apoptosis when exposed to Fas-specific antibody. 
Another study using hydrodynamic injection, investigated the use of siRNA in the treatment of acute 
liver failure in mice43. Caspase 8 was targeted as silencing of the caspase 8 gene inhibits Fas mediated 
apoptosis. They were able to demonstrate that treatment with siRNA was able to protect hepatocytes 
from apoptosis and therefore attenuate liver failure using this method of systemic delivery. 
  
Age-related macular degeneration (AMD) is the breakdown of the eye’s macula of the retina, which 
in some cases results from the abnormal growth of blood vessels and is often driven by vascular 
endothelial growth factor (VEGF). Elevated levels of VEGF are also associated with diabetic 
retinopathy46, and retinopathy of prematurity47. siRNA has been used as a therapy in in vivo studies 
conducted in both mice48 and primates49 to down regulate VEGF expression. These studies showed 
that siRNA targeting VEGF resulted in a decrease in neovascularisation. In another study, siRNA was 
used to target VEGF, VEGFR-1, VEGFR-2 and a combination thereof, and also resulted in a significant 
reduction in neovascularisation50. These studies delivered the siRNA via direct injection into the eye, 
an otherwise isolated organ. A number of clinical trials have also been conducted and have reached  
phase I & II stages of development24,32,51.  
 
Though the above are very promising findings, there is a significant drive towards improving siRNA’s 
half-life in vivo, its ability to cross the cell membrane, and to prevent immunogenicity via chemical 
modifications. Possible chemical modifications can be summarised into three different categories: 
internucleotide linkage modifications, sugar modifications, and nucleobase modifications (these 
include the incorporation of 2’-O-methyl and 2’-deoxy-2’-fluor groups)52. To improve the half-life of 
nucleotides in serum, modifications to the nucleotide linkages can be made in order to increase 
resistance to nuclease degradation. Sugar modifications made to the RNAi molecules can confer an 
increase in binding affinity for the target sequence. Modifications to the nucleobases can result in 
improved thermal stability and a reduction in immunogenicity.  
 
The biodistribution and efficacy of systemically delivered RNAi molecules have been assayed in a 
number of studies. In one such study, Lewis et al41., employed hydrodynamic injection to co-deliver 
anti-luciferase siRNA with a firefly luciferase plasmid to determine if gene expression can be repressed 
in various organs. One day post injection the animals were euthanised and the organs collected for 
analysis. It was determined that luciferase expression was reduced by 80 – 90% relative to the 
luciferase plasmid alone in the liver, spleen, lung, kidney and pancreas. Not surprisingly these are all 
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well perfused organs. Braasch and colleagues23 examined the distribution of modified siRNA. The 
group synthesised two siRNA molecules, the first with two phosphodiester  modified strands (PO/PO) 
and the second with one phosphodiester strand and one phosphorothioate strand (PO/PS) in an effort 
to improve the pharmacokinetic properties of siRNA. The PO/PS strand showed higher levels of 
stability having remained intact for up to 72 hours in murine serum at 37°C relative to the PO/PO 
strand which was fully degraded after 24 hours. The strands were then further labelled with 
radioactive iodine. Mice were injected with the different formulations and the blood, liver, kidney, 
heart, spleen, lung, and brain were collected for analysis at various time points. Both the PO/PO and 
the PO/PS radiolabelled RNA were found to have preferentially accumulated in the liver and kidney 
over the course of the experiment. The levels of PO/PS in the blood were significantly higher than the 
PO/PO strand possibly due to superior stability. The PO/PS strand showed increased distribution to 
the lung, spleen, heart and brain compared to the PO/PO strand after 4 hours, although relative to 
other organs these were low. The levels of siRNA measured decreased after 24 hours in all the organs, 
but decidedly less in the liver and kidneys, and persisted for the full 72 hours of the experiment for 
both forms of siRNA. Treatment using naked siRNA delivered in this manner would therefore appear 
to be best suited to treat well perfused organs such as the liver and kidneys.    
 
However, naked siRNA has its short comings that would make it less suitable for use in the clinic. As 
mentioned above naked RNAi oligonucleotides have difficulty crossing the cell membrane, a relatively 
short half-life in the blood due to the presence of RNases and systematically delivered siRNA is 
localised to the liver and kidneys and cleared from the system. Therefore high doses are required for 
there to be any noticeable effect36,53–55 and this increases the chances of off target effects. While it is 
possible that dosages could be lowered by localised injection as opposed to systemic, alternatives are 
still needed. 
 
1.2.2 Alternative vectors 
 
Alternative vectors have been proposed to help overcome some of the limitations surrounding the 
use of RNAi oligonucleotides, such as the difficulty that RNAi molecules have crossing the cell 
membrane and the negative consequences of using viral vectors. Nanoparticle formulations have 
been proposed as a possible means to surmount both the physiological and intracellular barriers. 
These formulations interact with the siRNA in a number of ways including electrostatically binding, 
passively encapsulating, or covalently attaching to the siRNA to form usually slightly cationic 
complexes53. A plethora of formulations exist which include, cell penetrating peptides, cationic lipids, 
and cationic polymers.  




The basic mechanism for cationic complexes to deliver RNAi cargo into the cell is as follows: The 
complexes bind to the cell surface via non-specific electrostatic interactions between the anionic cell 
surface and the cationic complexes and  gain access to the cell via endocytosis or endocytosis like 
mechanisms56.  Inside the endosome, the pH drops to 5.5 at which point some of the cargo escapes 
into the cytosol, the exact mode of endosomal or lysosomal escape differs depending on complex 
composition56. 
  
Below, studies that have investigated in vivo delivery with cationic vehicles are discussed with an 
emphasis placed on cationic lipids but more especially on cationic polymers as a cationic polymer was 
selected for use in this project. Multitudes of examples exist for each of the below sub headings, 
targeting a wide range of disease conditions, and are therefore too numerous to all be included here. 
Studies were selected as examples of the complexities and the delivery considerations involved in 




Cationic cell-penetrating peptides (CPP) also known as peptide transduction domains are short strands 
of approximately 30 amino acids which are arginine- and/or lysine-rich57. The ability of some proteins 
to enter cells was first reported in the HIV Tat protein towards the end of the 1980’s58,59. They are able 
to deliver the siRNA via direct penetration and/or existing endocytotic pathways which in general 
terms is a two-step process involving endocytic entry followed by endosomal escape60. The process 
can be activated via electrostatic interactions with cell surface proteoglycans or by direct interaction 
with the plasma membrane61. Endocytosis for CPPs and its cargo is via pinocytosis which can be further 
divided into four pathways: macropinocytosis, clathrin-mediated endocytosis, caveolae/lipid raft-
mediated endocytosis, and clathrin/caveolae-independent endocytosis. The specific pathways utilised 
are related to the chemical and physical properties of the peptides and their cargo62.   
 
As with other nanoparticle formulations to be discussed later, various CPP formulations have been 
used to deliver siRNA to a range of targets60 including those involved in cancer63,64 and HIV65. In 2016 
Welch et al66., reported on their use of a disulphide-constrained cyclic amphipathic peptide for the 
delivery of siRNA to cells in both in vitro and in vivo conditions. They were able to form non-covalent 
peptide siRNA complexes able to deliver siRNA into the cytoplasm. They demonstrated functional 
knockdown of the target gene expression of thyroid transcription factor-1 (TTF-1), a master regulator 
of cells in the thymus and lung, in human epithelial cells and mice when delivered locally. 
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Approximately 85% TTF-1 inhibition was achieved in A549 cells (human lung adenocarcinoma) and 
40% in H441 cells (also human lung adenocarcinoma). In an in vivo experiment, whole lung expression 
of TTF-1 was analysed and it was found that TTF-1 protein levels were lower in mice treated with the 
peptide formulation with TTF1 siRNA compared to peptides formed with scrambled siRNA controls. 
Despite this success their complexes showed instability and over a period of 24 hours were unable to 
protect the siRNA from degradation by RNases present in FBS. It was therefore concluded that the 
siRNA-peptide formulations were best suited for in vitro delivery and localised in vivo delivery but that 
they were not well suited to systemic delivery.  
 
There have also been concerns around the use of CPPs including cytotoxicity and immunogenicity 
which are caused by the disruption of the cell membrane67. The findings in the above study would also 
indicate that the use of CPPs is cell specific as they are not able to achieve the same levels of post 
transcriptional silencing in the H441 cell line compared to the A549 cell line. Other concerns regarding 
their use is the formation of insoluble aggregates - due to covalent interactions between the anionic 
siRNA and the cationic CPPs - which renders them ineffective and is an issue which is considered 
pivotal if CPPs are to be used succesfully68–71. 
 
1.2.2.2 Cationic lipids 
 
First developed for gene delivery in 198772, the use of cationic lipids has grown considerably73. Cationic 
lipids contain a positively charged polar headgroup which is linked to a hydrophobic domain rendering 
them amphiphilic56. They are often combined with a neutral helper lipid to form liposomes. When the 
liposomes interact with siRNA they form what are referred to as lipoplexes and are also sometimes 
known as lipopolyplexes especially when there is an addition of a polycation74,75. Structurally the 
lipoplexes have multiple lipid bilayers with the RNAi molecules located between adjacent layers. 
Lipopolyplexes differ in that the RNAi molecules are located at the core within a polymer complex75.   
 
To gain entry into the cell the lipoplexes bind to the cell membrane via non-specific ionic 
interactions76–78. Endo-lysosomal escape is initiated by destabilisation of the endosome by the cationic 
lipid. Once inside the endosome the cationic lipoplexes form ionic pairs with the anionic lipids of the 
endosome membrane which results in siRNA release from the lipoplex and destabilisation of the 
membrane leading to siRNA release into the cytoplasm79,80.  
 
Sheng and colleagues81 synthesised a lipid based nanoparticle using a natural steroid diosgenin 
cationic lipid (Diosarg) to which they added a 1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine 
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(DOPE) (a neutral lipid often used as a helper lipid) head group (Diosarg-DOPE). They showed that the 
addition of DOPE resulted in improved siRNA internalisation compared Diosarg alone.  Diosarg-DOPE 
(1:1, 1:2 and 2:1)/ Cy3-siRNA nanoparticles displayed 1.77, 2.10 and 2.77-fold increases in siRNA 
internalisation compared to Diosarg/Cy3-siRNA complexes alone measured by flow cytometry. 
Warashina et al82., developed a novel cationic lipid based formula called YSK12-C4 to which they added 
a multifunctional envelope-type device (MEND) – also a lipid based nanoparticle – to target dendritic 
cells (DCs). Scavenger receptor class B type 1 was selected for gene knockdown experiments as it is an 
endogenous gene in bone marrow DCs. Their YSK12-C4 formulation achieved more than 90% 
knockdown compared to RNAi max which achieved a mere 57% in vitro. Both of these groups showed 
promising results, both having reported low cytotoxicity and high levels of transfection while only 
Warashina et al., demonstrated in vivo gene knockdown achieving significantly higher levels of gene 
silencing relative to the commercially available Lipofectamine RNAiMAX.  
 
In another study Lee et al.,83 developed a neutral nanoparticle termed small lipid nanoparticles (SLNPs) 
which were made of the cationic cholesterol derivative – mono arginine-cholesterol – and the neutral 
helper lipid DOPE as the major constituents and, a small amount of PEGylated phospholipid mixed 
with siRNA, for systemic delivery of siRNA for cancer treatment. Nanoparticles were between 45 and 
52 nm in size and displayed low cytotoxicity both in vitro and in vivo. After 6 hours in 30% FBS at 37°C, 
75% of the encapsulated siRNA was still present and 40% after 24 hours while naked siRNA was 
completely degraded within 3 hours. Kinesin spindle protein was targeted for efficacy experiments as 
it plays an important role in mitosis and is overexpressed in cancer cells. Its inhibition has been found 
to result in mitosis cessation and cell death. Gene silencing of 75% at a 1:1 (siRNA:SLNPs) molar ratio, 
and 68% at a 1:2 ratio was observed in PC-3 human prostate cancer cells. In the presence of serum 
the efficacy was markedly reduced at approximately 51% for the 1:1 ratio. In a prostate cancer mouse 
model the preferential accumulation of their siRNA-SLNPs at the target site (the tumour) was found 
after systemic injection and tumour growth was dose-dependently inhibited. Tumour growth was 
inhibited by 81% in mice who received a high dose treatment while mice receiving a low dose showed 
tumour growth inhibition of 58% relative to the saline controls.  
 
Various other lipoplex formulations have also been used to target solid tumours and were able to 
demonstrate a reduction in tumour size84–87. Others have used lipoplex formulations which they 
applied directly to a target area and were able to effectively silence herpes proteins and protect mice 
from being infected with herpes simplex 2 virus88. They have also been used to deliver siRNA to a range 
of other targets with beneficial outcomes including preventing sepsis development89, and reducing 
Literature Review   
12 
 
low density lipoprotein (LDL)  and serum cholesterol levels90. Lipids therefore hold a great deal of 
potential However, it has also been previously reported that lipids can induce an immunological 
response91. 
 
1.2.2.3 Cationic polymers 
 
Cationic polymers, like cationic lipids above, were originally introduced for gene delivery as far back 
as 198792, since then they have been used for both in vitro and in vivo delivery of nucleic acids56. A 
variety of cationic polymers have been fabricated from both naturally and synthetically derived 
materials including; dendrimers, poly(L-lysine) (PLL), cyclodextrins, chitosans  and poly(ethylenimine) 
(PEI). The polycationic polymers form nanoparticles, also known as polyplexes, with nucleic acids by 
electrostatic interactions between the positively charged functional groups – often amines – and the 
negatively charged phosphate groups present in nucleic acids producing a particle with either a 
positive or neutral charge. Cationic polymers are able to form relatively small nanoparticles with 
oligonucleotides, a favourable characteristic for gene transfer.  
 
Some cationic polymers are able to successfully deliver their cargo to the cytoplasm via the proton 
sponge effect which improves endosomal release79,93–95. Polyplexes which have a high buffering 
capacity are able to stop the acidification of endosomes. This in turn increases the influx of protons 
and counter ions inside of the endosome. The increase in counter ion concentration leads to osmotic 
swelling, followed by membrane rupture and release of the siRNA into the cytosol96,97. 
  
Compared to cationic lipids, cationic polymers do not have a hydrophobic domain and are completely 
soluble in water56. They also have an advantage in that they are more easily and more economically 
produced, can be synthesised to different specifications, including the addition or substitutions of 
functional groups, and can form smaller nanoparticle complexes. As such a variety of structures are 
possible, and polymers used can be synthesised to various specific lengths and geometries (linear or 
branched). Due to the potential for modification, the use of these cationic polymers holds promise for 
the future. This is because any potential disadvantages associated with the use of some of these 
polymers, including cytotoxicity and weak electrostatic interactions between the siRNA and polymer, 









Poly(L-lysine) (PLL) is a first generation cationic polymer, that is biodegradable – a favourable 
characteristic to have in vivo56. PPLs of different molecular weights are produced by the cationic 
polymerisation of lysine N-carboxy anhydrides98,99. Often, owing to poor delivery, PLL is modified with 
PEG100, mesoporous silica101 and dendrimers102 in order to improve this99,103.  
 
In one such study PLL was modified with a sixth generation dendrimer before being complexed with 
siRNA to treat hypercholesterolemia in in vivo studies102. The PPL molecule termed KG6 was used to 
deliver siRNA targeting Apolipoprotein B (ApoB) (an essential protein for the formation and secretion 
of very low density lipoprotein and LDL during the metabolism of cholesterol) to hepatocytes in vivo. 
KG6 siRNA complexes were delivered to healthy mice via intravenous injection and a reduction of 
ApoB mRNA was observed in a dose dependent manner, with an up to 50% reduction in the mice 
receiving the highest dosage compared to control mice 24 hours after delivery without hepatotoxicity. 
Improvement in hypercholesterolemia was also observed after treating Apolipoprotein E (important 
for catabolism of triglycerides-rich lipoproteins) deficient mice with KG6 anti-ApoB siRNA.  
 
Though successful examples of its use are reported, such as above, it should be noted that, compared 
to other cationic polymer transfection agents, PPL complexes have very low transfection capabilities 
due to being ineffective at endosomal escape (even with modifications, due to a lack of primary 
amines97) and are rapidly removed from circulation as they bind to plasma proteins56. Even when 




Dendrimers are synthetic polymers made up of multiple covalently bonded branched monomers 
forming a spherical shape. They consist of an inner core and an increasing number of radially attached 
branches emanating from the core. Each new layer of branches is termed a “generation” and is built 
up by the addition of methyl acrylate and amines105. The higher the number of branches, and therefore 
the generation, the higher the number of surface groups and charge density which offers the potential 
for multiple interations53,56,95. Cationic dendrimers have amine surface groups which assist with 
complexing the anionic RNAi molecule and aid in resisting degradation by nucleases. The amines also 
facilitate endosomal escape via a proton sponge effect95.  
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Poly(ethylene) glycol monomethyl ether was used to modify fifth and sixth generation (G5 and G6) 
poly(amidoamine) (PAMAM) dendrimers and investigated for intramuscular siRNA delivery106.  Their 
PEGylated G5 and G6 dendrimers were shown to be stable over 4 hours in RNase A compared to the 
uncomplexed siRNA which was degraded within 5 minutes. The PEGylated forms of both the G5 and 
G6 dendrimers were significantly less cytotoxic compared to unmodified dendrimers and were able to 
achieve significantly higher levels of FITC siRNA internalisation in primary vascular smooth muscles 
cells (VSMC) (5-7 fold higher) and macrophage cells (26-27 fold higher) compared to a commercially 
available transfection reagents. Efficacy experiments targeting GFP expression were conducted by co-
delivering pEGFP with anti-GFP siRNA to 293 A cells. The G5 PEGylated dendrimer achieved the highest 
levels of GFP inhibition (66%) which was equivalent to that achieved with the commercial transfection 
reagent, Lipofectamine 2000. In vivo experiments were conducted in GFP transgenic mice as well as 
in neonatal C57BL/6 mice. C57BL/6 mice were injected in the quadriceps with Ad-GFP 2 hours prior to 
injection with dendrimer complexes. A 55% reduction in GFP expression in mice anti-GFP siRNA 
complexed with G5 or G6 PEGylated dendrimer was observed in the neonatal mice while a 44% 
reduction was observed in the GFP transgenic mice. 
 
Although dendrimers can be manufactured to exact molecular weights, sizes and geometries and can 
be designed to achieve targeted drug delivery, concerns around toxicity and high manufacturing costs 
exist95,107. Despite this they have been used to modify other nanoparticle formulations such as PLL and 
cyclodextrins. 
 
1.2.2.3.3 Cyclodextrins  
 
Cyclodextrins (CDs) were originally used for pDNA delivery but were later re-optimised for siRNA 
delivery and have made it to the clinical trial stage for the treatment of cancer108–110. They are cyclic 
oligosaccharides which come in three forms; α, β and γ-CDs, however β-CD is most commonly used 
for delivery111. The β-CD are composed of seven glucose units connected by α-1, 4-linkages4. They 
have been favoured due to low cytotoxicity levels and lack of immunogenicity. CD molecules have a 
hydrophilic outer surface and hydrophobic core which can encapsulate the RNAi molecules for 
delivery, a process mediated by amidine functional groups109. The further addition of imidazole 
functional groups aids in endosomal escape and therefore enhanced delivery112.   
 
Although unmodified CD particles have been used for in vitro testing it was found that for in vivo 
studies chemical modifications to the CD molecules were necessary to assist with siRNA complexation, 
and to prevent aggregation thereby prolonging systemic circulation22,113. Many studies conducted 
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around the use of CDs for siRNA delivery have centred on cancer associated targets108,110,114–117. Other 
diseases and targets include acute colitis118 and Huntington’s disease119, the central nervous system120 
and the liver121. 
 
In a recent advance in the use of this polymer, and an example of a modified CD, Guo and collegues115 
developed an antibody targeted CD based nanoparticle to selectively down regulate leukemic stem 
cells, in patients with acute myeloid leukaemia (AML)122. CD was modified via PEGylation for 
stabilisation, and the addition of an antibody for IL-3 receptor α-chain (a receptor highly expressed in 
target cells). siRNA targeting bromodomain-containing protein 4 (BRD4) (a therapeutic target of 
AML123) was encapsulated with the modified CD nanoparticles and used to transfect KG1 cells (an AML 
cell line). BRD4 mRNA expression was inhibited by 40% compared to the control while protein 
expression was inhibited by approximately 50% compared to the control. Cells treated with the CD 
nanoparticles displayed significantly higher levels of cell death (approximately 40%) compared to cells 
treated with negative control siRNA. The therapeutic potential of CD delivery of siRNA was further 
assessed ex vivo using primary culture leukocytes from newly diagnosed and relapsed AML patients. 
The mRNA and protein levels of BRD4 in leukocytes from newly diagnosed patients were reduced by 
approximately 40 and 45% respectively and were able to demonstrate myeloid differentiation, a 




Chitosan is a polysaccharide derived from the deacetylation of chitin found in either fungi or the shells 
of crustaceae. Chitosan is a copolymer of β-(1,4)-2-acetamido-D-glucose and β-(1,4)-2-aminoD-
glucose124. A naturally occurring cationic polymer, chitosan has formed the basis of some hydrogels125 
and has been used in nucleic acid delivery126–129. Chitosan based nanoparticles are considered 
favourable carriers due their high positive charge, biocompatibility, and low levels of cytotoxicity and 
immunogenicity129,130.  
 
Chitosans have been used successfully to silence target genes both in vitro and in vivo4. Targets of 
chitosan siRNA formulations include CDX2 factor which is involved in gastrointestinal maintenance131, 
targets associated with  cancers132–135 such as galactin 1 which is associated with tumour progression, 
platelet-derived growth factor B in a rabbit iliac artery injury model136, as well as genes associated with 
neuroregeneration137 and brain endothelial cells138.  
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Sadreddini et al132., looked at the potential of delivering both doxorubicin (DOX) – a drug used in 
chemotherapy – and siRNA in combination, for the treatment of colorectal cancer. The group 
combined carboxymethyl dextran (CMD) with chitosan to form DOX-snail siRNA CMD-Chitosan 
nanoparticles (ChNP). The Snail family of transcription factors are mediators of epithelial-
mesenchymal transition that has been shown to down regulate E-cadherin – an adhesion protein 
which is anti-tumourgenic. CMD is an anionic derivative of dextran which allows for the addition of 
chemical conjugates such as drugs. The authors report that their nanoparticles were stable, after 
placing samples in FBS or heparin to represent physiological conditions. The authors were also able to 
demonstrate that their nanoparticle was able to achieve significantly higher levels of drug and siRNA 
delivery in an acidic environment compared to a neutral one, much like one would find in a tumour. 
 
Chitosans have many favourable characteristics such as being both biocompatible and 
biodegradable139–141. However, unmodified chitosans are also considered to have poor solubility at 
physiological pH, low buffering capacity and have previously been considered to have low in vivo 
stability and inadequate intracellular release139. Therefore, as with many of the other formulations 
highlighted here, modifications are required to improve in vitro delivery as was done by Sadreddini et 
al132. 
 
1.2.2.3.5 Polyethylenimine (PEI) 
 
Polyethylenimine (PEI) is a commercially available cationic polymer also originally used to deliver 
pDNA142, but has subsequently been used to deliver siRNA143–145 as well as other oligonucleotides142,146. 
It is considered the gold standard147,148 amongst polymer based delivery systems and other non-viral 
vectors and delivery methods are often modelled on PEI due to its success both in vitro and in 
vivo142,147–150. It is generally accepted that PEI mediated siRNA entry is via clathrin mediated 
endocytosis, although like CPPs (section 1.2.2.1) above, this can vary depending on the physiochemical 
properties of the complex151. PEI is also understood to escape lysosomal degradation which is believed 
to be one of the main obstacles to overcome in cellular delivery of nucleic acids93,152. This occurs via 
the proton sponge mechanism, PEI has a buffering capacity due to protonation of the amines allowing 
it to regulate the pH inside endosomes93. The buffering capacity of PEI results in osmotic swelling and 
leads to the endosomes rupturing causing the release of the siRNA into the cytoplasm93.    
 
PEI has been used to deliver DNA and or siRNA to a range of targets including cancer cells153–158, the 
central nervous system159,160, the pulmonary system161,162 and cardiomyocytes145,163,164 and has been 
extensively used in vivo155,156,159,160,162,163,165–167.  




PEI is made up of repeating units composed of an amine and two aliphatic carbons. As such it is 
available in different geometries and sizes. Broadly, the different structures can be summarised as 
being low or high molecular weight and linear or branched. Kwok et al144., conducted a comparative 
study of linear (L-PEI) and branched (B-PEI) PEI to determine if the optimal criteria for delivery of siRNA 
and pDNA were the same as it is often the case that a selected vector for siRNA is chosen based on its 
effective pDNA delivery. Multiple aspects were considered including the binding and dissociation 
properties, the size and surface charge, internalisation, and efficacy. Polyplex formation is according 
to the ratio of nitrogen in PEI to phosphate in siRNA (N:P). It was determined that the optimal 
formulation for siRNA was B-PEI (20:1) while for pDNA L-PEI (10:1) was found to be optimal after 
comparing the various factors.  For pDNA L-PEI was able to achieve higher levels of transgene 
expression, smaller size and lower surface charge compared to B-PEI. However, the B-PEI DNA was 
considered to be more stable (determined by heparin dissociation assay). At a ratio of 20:1, B-PEI to 
siRNA gene inhibition of approximately 60% was observed while at the same ratio for L-PEI there was 
no effect. B-PEI-siRNA complexes were also considered more stable, and smaller compared to L-PEI-
siRNA. Similar results have been reported about the lack effectiveness when using L-PEI to deliver 
siRNA94.  
 
Structural difference between the pDNA and siRNA as well as between the L-PEI and B-PEI could 
explain the differences seen in delivery. siRNAs are smaller and more rigid structures compared to 
pDNA. The branched nature of the B-PEI could present more favourable complexing options for the 
siRNA which the L-PEI does not possess. By contrast, the larger structure of pDNA is better suited to 
complexation with linear PEI. Similar observations have been made with high (more flexible structure) 
and low (more rigid structure) molecular weight chitosans168. Another possible factor which could 
influence cellular uptake of siRNA and indicate why the 20:1 ratio was found to be optimal is the 
amount of free PEI available, as it has previously been shown that the presence of PEI in excess 
facilitates uptake169–171. 
 
Some have modified PEI complexes in order to improve transfection capabilities and in vitro and in 
vivo safety profiles. This includes modifications to aid cell entry and endosomal escape, cell targeting 
and particle stability, as well as decrease levels of cytotoxicity and improve delivery to target cells. 
Lowering the charge of complexes with modifications such as hyaluronic acid (HA) can improve toxicity 
but also help in cell targeting and PEI modified in this manner has been shown to improve in vitro 
silencing and reduce protein binding53.  




Hong et al164., had promising results using a linear PEI modified facial amphipathic deoxycholic 
acid(DA-PEI) to deliver siRAGE (siRNA RAGE) targeting receptor for advanced glycation end-products 
(RAGE), a known anti-inflammatory target,  to rat cardiomyocytes. Their nanoparticle was shown to 
have low cytotoxicity and were able to successfully transfect rat cardyomycyte cells (H9C2). Under 
hypoxic conditions, they demonstrated a reduction in apoptosis compared to non-treated cells with 
80% of non-treated cells exhibiting apoptotic nuclei versus 21% of treated cells. In in vivo experiments, 
nanoparticles were delivered via 3-intra-myocardial injections 1 hour prior to occlusion of the left 
descending artery of the heart. They were able to demonstrate a reduction in RAGE expression using 
siRAGE/DA-PEI in the ischemic myocardium and a reduction in infarct size and fibrosis in myocardial 
ischemic tissue pre-treated with siRNA/DA-PEI. 
 
Wang and colleagues145 modified PEI with hydrozide groups (PEI-HYD) – to neutralise the charge – and 
RGD (PEI-HYD-RGD) – a cell binding peptide – for siRNA delivery into an adult zebrafish heart injury 
model. Results were compared to unmodified PEI as well as siRNA alone. In in vitro experiments using 
HUVEC cells, both nanoparticles displayed no cytotoxicity with cell viability being maintained at 
increasing concentrations of polymer while unmodified PEI was considered toxic at all concentrations 
measured. They also looked at siRNA internalisation as well as the efficacy of transfected siRNA. Their 
PEI-HYD was the most efficient and they were able to demonstrate siRNA delivery to the cell and 
localise it to the cytoplasm surrounding the nucleus whereas transfection using the PEI or PEI-HYD-
RGD was more homogenously spread throughout the cytoplasm. During in vivo assessment however, 
their hydrazide modification fell short and was not as efficient at delivery as compared to their PEI-
HYD-RGD modification. The PEI-HYD-RGD was able to deliver higher levels of Cy5-labeled siRNA into 
the heart of zebrafish, and was also able to achieve higher levels of silencing. The unmodified PEI while 
superior to naked siRNA, uptake levels were still significantly lower than the PEI-HYD-RGD. This study 
suggests that use of a neutral or slightly positive (± 10 mV) polymer should be further explored for 
delivery.  
 
As is evidenced here, many polymers both natural and synthetic exist which can and have been 
exploited for oligonucleotide delivery. PEI is one of the most widely used molecules due to it’s 
effectiveness at delivering RNAi molecules and is commonly used in vivo165,172. However, high levels of 
cytotoxicity have also been reported limiting its progression as a therapeutic delivery vehicle13,173. 
Potential modifications can be made to improve not only the cytotoxicity but also improve 
transfection13,145. 
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1.3 Scaffolds for localised sustained delivery 
 
As outlined above, systemic delivery is plagued by two major issues namely degradation by 
ribonucleases and rapid clearance to the liver and kidneys23. Furthermore the potential for other 
complications including immunogenicity and toxicity, the potential for aggregation and undesirable 
accumulation, and off target gene silencing can also complicate delivery. Naturally these factors have 
a very unfavourable impact on the ability to deliver sufficient dosages of RNAi oligonucleotides at the 
desired target sites in the body. One approach by which this goal can possibly be achieved is through 
the systemic delivery of very high dosages. However, this strategy significantly elevates the potential 
for undesirable off target effects, both at the level of non-target tissue / organs and also non-target 
mRNA sequences. It has been shown that the down regulation of off target sequences occurs at 
moderately high dosages and that low dosages are required to offset this undesirable consequence174.  
It is the appreciation of this delivery problem that raised interest in the use of scaffolds, in particular 
hydrogels, as a possible means by which localised and more efficacious delivery might be relatively 
simply realised10,54. 
 
1.3.1 Biomaterials used for scaffold based delivery 
 
Biomaterials are materials which are biologically compatible and may be made from either a synthetic 
or biological material. They can be used throughout the body as part of an implant or biological device 
as well as on their own. They can also be specifically designed to either work alone or in synergy with 
a complex system via interactions with living components to control any therapeutic or diagnostic 
procedure where they are used175.   
 
Depending on the material used in these scaffolds, the structural and functional characteristics can be 
manipulated to display different properties based on a given need.  This is determined by the final 
clinical application of a given scaffold and the chosen form of release. A selected scaffold needs to be 
compatible with both the site of delivery and the RNAi agent it is to deliver. During fabrication of the 
scaffold containing RNAi molecules, the methods used must form the scaffold without damaging the 
RNAi therapeutic. Any potential protection the scaffold provides from nuclease degradation in 
addition to that from systemic clearance would also be of benefit. A biodegradable scaffold is desirable 
as it would eliminate the need to remove the scaffold post treatment and as such improve a patient’s 
prognosis54. The most necessary characteristic is for the fabrication or implantation of the scaffold not 
to be the cause of more harm at the site of implantation. 
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Biomaterial based scaffolds which have been used for RNAi delivery include hydrogels, surface 
coatings, fibres, and microspheres. The main focus of this work is toward the use of hydrogels to 
deliver RNAi therapeutics, however the potential of other biomaterial based scaffolds will also be 
discussed briefly below. 
 
1.3.1.1 Surface coatings 
 
There is potential to be found in modifying the surfaces of implants to deliver therapeutics, as surfaces 
of pre-existing devices or implants can be easily modified with a multi- or single-layered film or 
hydrogel to release RNAi molecules. The  coating of surfaces with RNAi therapeutics can be employed 
to enhance the therapeutic potential of surgical implants or other devices implanted into the body – 
including to aid in device tolerability. RNAi molecules as well as other therapeutics have been 
incorporated into surface coatings to induce gene silencing176–179, and treat ailments including bone 
defects180, and others180–183 with beneficial therapeutic outcomes.     
 
Joddar et al179., incorporated siRNA into dopamine coated stainless steel surfaces. The aim was to 
eventually develop a method for RNAi delivery from stainless steel surgical implants such as 
intravascular devices. Stainless steel discs were submerged in a solution of dopamine, at either acidic 
pH to form a monolayer or at a basic pH which resulted in a multilayer both with exposed amine 
groups before discs were coated with various concentrations (0.3 – 10 µM) of anti-luciferase siRNA. 
Both surface coatings were able to retain similar amounts of siRNA compared to untreated surfaces 
of control discs (optimum concentration of 0.625 µM siRNA). They were also able to achieve both 
localised and sustained delivery of siRNA for at least 7 days on both forms of coated surface in vitro, 
and demonstrated reduced cytotoxicity compared to traditional transfection methods using 
Lipofectamine. Discs were then coated with Egr-1 siRNA, a transcriptional regulator of many genes 
involved in cell migration and mitogenesis in smooth muscle cells which are important factors in 
atherosclerotic lesion formation184. In an experiment to mimic the elution of siRNA from a stent in 
vivo, human aortic smooth muscle cells (HAoSMC) were seeded in 24-well plates, allowed to grow, 
before placing a coated stent centrally in the well. They were able to show a significant reduction of 
Egr-1 protein expression and proliferation inhibited in HAoSMCs for both surfaces compared to cells 
treated with scrambled siRNA eluted from either surface or bare discs.  
 
Castleberry and colleagues185 used a technique where they assembled layer-by-layer ultrathin polymer 
films, on oxygen plasma treated sutures, with siRNA incorporated within. Hydrolytically degradable 
base layers of Poly 2 (a polycation) and dextran sulfate were formed by submerging the sutures in 
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alternating solutions of the two using a slide stainer. A similar process was followed to form alternating 
layers of chitosan and siRNA for the siRNA incorporation layers. In this study they used this technique 
to coat commercially available silk sutures with siRNA to promote wound healing in a third-degree 
burn model in rats. siRNA targeting connective tissue growth factor (CTGF), was targeted. CTGF  is 
known to interact with transforming growth factor-beta (TGFβ), which has previously been shown to 
be associated with increased fibrosis, when upregulated186. They were able to demonstrate CTGF 
inhibition (approximately 36% compared to controls) which resulted in the altered expression of genes 
associated with scar formation. There was also evidence of tissue remodelling, and a reduction in scar 
formation.  
 
This approach certainly has promise in optimising responses to implanted devices or in wound healing. 
However, due to their nature, the use of these kinds of films is somewhat limited as they are not 
injectable. The need to place some sort of implant also may not be as easily achieved in less accessible 
organs. 
 
1.3.1.2 Electrospun NanoFibres 
 
Electrospun nanofibres offer another alternative for siRNA delivery. Electrospinning is a versatile 
process which offers the researcher the possibility to produce wafer thin scaffolds made up of 
continuous fibres. Using this technique it is possible to produce scaffolds of nanofibres which resemble 
the structure of the extracellular matrix. It is also possible to orientate the specific fibres and alter the 
pore and fibre size depending on a given need. They have a high surface area to volume ratio, resulting 
in many cellular attachment sites which allows for a high degree of cellular and drug interactions187. 
The successful release of siRNA from electrospun nanofibres scaffolds has been examined. These 
include fibres made using poly(caprolactone) (PCL) and Poly(ethylene) glycol (PEG),188 copolymers of 
PCL and ethyl ethylene phosphate (EEP),189 and poly(D,L-lactic-co-glycolic acid) (PLGA)126.   
 
In an in vitro study, Low et al190., used PCL in combination with polydopamine (PD) to form scaffolds 
in to which they incorporated anti-REST siRNA (REST is a transcriptional regulator for many neuronal 
specific genes, which control the expression of ion channels, synaptic vesicles and 
neurotransmitters191,192) with the aim of increasing differentiation of stem cells into neuronal cells. 
Further exploitation of the scaffold was leveraged by the provision of topographical cues that might 
enhance stem cell differentiation towards neural cells. Briefly, PCL was electrospun into scaffolds, and 
then soaked in PD for four hours, siRNA was then complexed with the commercially available 
Lipofectamine RNAimax before being incorporated into PD-fibre scaffolds which were then lyophilised 
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overnight. The scaffolds were coated in laminin (protein found in basal lamina of epithelia) before 
being seeded with murine neuronal progenitor cells (NPCs). They were able to transfect cells with 
siRNA using their PD-fibre scaffolds and demonstrated enhanced neuronal differentiation by 
topographical effect and gene knock down in vitro. Also using NPCs, they demonstrated REST silencing 
for up to five days. They were also able to show, that in combination with gene knock down, the 
topographical cues provided by the scaffolds resulted in significantly higher levels of NPC neuronal 
commitment, and lower levels of glial cell differentiation. This demonstrates the potential synergy 
that can exist between RNAi therapeutics and delivery method.   
 
Nanofibre scaffolds such as these are not injectable, thus this form of therapeutic delivery would be 
most suited as therapeutic patches for burn wounds or lesions. Another limiting factor of electrospun 




Hydrogels are highly hydrated structures at more than 90% water and are formed by covalent or non-
covalent interactions between either synthetic or non-synthetic hydrophilic polymer chains. The 
hydrogels structure is similar to that of the extracellular matrix (ECM), making them compatible for 
use in many tissue types. Hydrogels have long been recognised and utilised as very engineerable 
localised drug depots193. The tuneable nature of their chemistry allows the release of the drug by the 
biomaterial to be finely controlled through parameters such as steric entrapment and chemical drug-
scaffold interactions. Additionally, the scaffolds can be engineered such that their rate of release can 
be altered by biological stimuli such as pH194–196 and cellular degradation197. Their hydrophilicity also 
allows for potentially facile incorporation of hydrophilic oligonucleotides. As such, they are considered 
to be a good candidate for biomedical applications including as eluting reservoirs for RNAi 
oligonucleotides as well as other therapeutics54. The use of hydrogels overcomes many of the 
drawbacks associated with systemic delivery including the need for high repeated dosages, toxicity, 
and undesired accumulation. By localising treatment using a hydrogel,  drug retention and release to 
a target area are promoted and in doing so, the concentration required for a given therapeutic to be 
effective is reduced198,199.  
 
Material selection is an important aspect to consider to achieve localised RNAi delivery.  As previously 
mentioned hydrogels are composed of either synthetic or non-synthetic polymers. Non-synthetic or 
naturally derived materials include collagen, fibrin, chitosan and hyaluronic acid (HA). These materials 
have often been used to form hydrogels as they are biocompatible and either are part of or have 
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similar properties to that of the naturally occurring ECM200. These naturally derived hydrogels are also 
favoured for their intrinsic cellular interactions and cell facilitated degradation54,200. However, it is 
difficult to manipulate their specific properties and, due to their biological origins, they run the risk of 
inducing an immune response limiting their use in the clinic201.  
 
Synthetic hydrogels are highly attractive due to their reproducibility and modifiability. Examples of 
synthetic hydrogels include PEG, poly(ethylene oxide) (PEO), and poly(vinyl alcohol) (PVA). 
Synthetically derived hydrogels lack the intrinsic cellular interactions seen in non-synthetic hydrogels, 
and often require modification to render them more cell compatible.  
 
In many instances it is often desirable that the hydrogel is degraded once the RNAi oligonucleotides 
have all been delivered. The crosslinking methodology can also alter the degradability of the hydrogel 
and in turn influence the release rate. Hydrolytically degradable crosslinks allow for the gradual 
breakdown of the hydrogel. In a more sophisticated approach, enzymatically degradable crosslinks 
can be used that allow for cell dependent degradation of the gel197,201–203. Control of the monomer size 
and extent of crosslinking will regulate pore size and allows for further control of release rates by 
steric hindrance. This also allows for the control of mechanical parameters such as stiffness. It can 
certainly be envisaged that consideration of both delivery rates and the mechanical nature of the 
hydrogel will be important in instances such as delivery to the heart after myocardial infarction204. A 
gel that can relieve stress and also control the release of a cardioprotective siRNA would be desirable. 
 
The method of delivery can also be selected; gels can either be injected or surgically implanted. 
Injectable hydrogels can be administered in a minimally invasive way. Surgically implanted hydrogels 
are formed prior to implantation in a controlled environment and as such they do not run the risk of 
diffusing away from the target site or undergoing gelation prematurely which could result in delivery 
failure. 
 
1.4.1 In vitro analysis of RNAi delivery using hydrogels. 
 
Understanding release kinetics of and cellular interactions with hydrogel based delivery systems are 
essential in furthering their development. In addition, assessing the bioactivity of any RNAi 
oligonucleotides which may be enmeshed should be considered.  
 
Krebs et al205., were the first to report on the localised and sustained delivery of siRNA in vitro. They 
employed three different hydrogels which were all biodegradable and potentially injectable for their 
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experiments. These hydrogel formulations were a calcium crosslinked alginate, photocrosslinked 
alginate, and collagen. They used a siRNA targeting destabilised Green Fluorescent Protein (deGFP) 
(half-life of approximately 2 hours, versus enhanced GFP which has a half-life of 24 hours) for their 
experiments. The group reported sustained release of siRNA of approximately one week for the 
alginate based hydrogels and approximately two weeks for the collagen gels. The photo-, and calcium 
crosslinked alginate gels released the most siRNA in that order, followed by the collagen. They noted 
that the addition of chitosan or PEI to the calcium crosslinked alginate reduced the release rate. 
Bioactivity of released siRNA was assayed by co-culture using transwells. Cells expressing deGFP were 
seeded in a monolayer while hydrogels containing siRNA were suspended above in the permeable 
transwell. The released siRNA inhibited GFP expression by 80% compared to the no treatment 
controls. The ability of incorporated siRNA to transfect cells entrapped within the same hydrogel was 
assessed in the photocrosslinked alginate and collagen gels. Briefly, the different formulations were 
mixed with anti-deGFP siRNA and deGFP cells before gelling. After 3 days significant GFP inhibition 
was recorded for both gels, however after 6 days GFP expression for the photocrosslinked gel had 
increased while in the collagen hydrogel it continued to inhibit GFP expression at 6 days. This is in 
accordance with the results of their release profile experiments as collagen was able to sustain release 
for a longer period. However, it should be noted that mixing the cells and gels together in this manner 
is not a true reflection of in vivo conditions. By mixing the cells together with the siRNA before gelation, 
there is substantial risk of transfecting cells prior to polymerisation of the hydrogel. Under true in vivo 
conditions this would not be the case as the siRNA would need to be released by the hydrogel, or cells 
would have to first invade the hydrogel before coming into contact with the siRNA. 
The differences in release profiles noted in the above study were attributed to the highly anionic 
charge of the alginate polymer and the probable repulsion of the anionic naked siRNA. In a follow up 
study by members of the same group, they noted that release of siRNA from alginate and collagen 
hydrogel systems was not easily controlled and that it was necessary to develop a hydrogel that would 
allow for better controlled, localised and sustained delivery of siRNA206. A photo cross-linked dextran 
hydrogel, into which they covalently incorporated the cationic polymer LPEI via biodegradable ester 
linkage, was developed to enable modifiable controlled degradation206. Release rate was determined 
by hydrogel concentration, 8% w/w hydrogels degraded and released the siRNA over 9 days whilst 
12% w/w hydrogels degraded and released the siRNA over 17 days. The bioactivity of released anti-
deGFP siRNA was assessed by transfecting cells with siRNA eluted and collected after 3, 7 and 14 days. 
deGFP inhibition was reported of approximately 90, 60 and 75% when using siRNA collected after 3, 7 
and 14 days respectively. Aggregation has been reported to occur for PEI nanoparticles56. The surface 
charges, particles including PEI have previously been reported to aggregate in a time dependent 
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manner56. This time dependent aggradation has previously been reported to occur at a faster rate for 
LPEI than for BPEI207. These are important considerations as with aggregation comes an increase in 
particle size which affects the ability of the nanoparticle complex to deliver the siRNA. Complexes 
should be between 50 to 200 nm in order for internalisation via endocytic pathways to occur208,209. 
This does not appear to have played a role here and maybe due to its conjugation to dextran. 
 
Similar experiments were also conducted using PEG hydrogels which formed via thiol-acrylate 
reactions thereby removing the need for photo-polymerisation, and avoiding potentially harmful 
exposure by the incorporated cells and other biologically active factors210. Here PEI (25 KDa 
Branched)/siRNA nanoparticles were formed prior to being incorporated into the PEG hydrogels using 
anti-GFP siRNA. The PEG hydrogels were crosslinked using another PEG containing sulfhydryls at the 
termini. Every 5 days releasate was collected and replaced. Cells were treated with releasate collected 
on the final day (day 42) before complete gel degradation due to hydrolysis as well as with freshly 
prepared PEI/siRNA complexes. The expression of deGFP after treatment with the releasate and 
freshly prepared particles was silenced to 10-25% of untreated cells, indicating that bioactivity was 
maintained. It is perhaps surprising that PEI aggregation did not play a role here. The overall aim in 
this study was to use the siRNA containing hydrogels to promote osteogenic differentiation of 
mesenchymal stem cells (MSCs). Following on from the release studies the group formed 
nanoparticles using anti-Noggin siRNA and miRNA-20a which were delivered separately or in 
combination to encapsulated MSCs in an effort to promote osteogenic differentiation. Noggin is an 
antagonist of bone morphogenetic proteins (BMP) -2, -4, -5, -6 and -7 and its expression is promoted 
by BMPs via negative feedback. miRNA-20a down-regulates the expression of peroxisome 
proliferator-activated receptor gamma (PPAR-ϒ), a negative regulator of BMP-2. A significant 
reduction in Noggin mRNA levels was observed at all time points measured over 28 days. PPAR-ϒ 
expression remained unchanged in the anti-Noggin siRNA group, but was significantly lower in the 
miRNA-20a group and combination treatment groups at 7 and 14 days, while only the miRNA20a 
group remained significantly low at 28 days. Mineralisation of hydrogels was determined and a higher 
calcium content was found in the combination groups and anti-Noggin siRNA groups. The group was 
able to engineer a hydrogel which was shown to release siRNA in a sustained manner and which can 
be used to control stem cell fate.        
 
As previously discussed hydrogel systems can be designed to respond to different external 
environmental stimuli such as temperature, light, enzymatic activity, electricity and pH to promote 
RNAi elution.   Huynh and co-workers211 incorporated an aminoethyl methacrylate, a cationic 
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molecule, into an acrylated PEG hydrogel. Particle release could be controlled by exposing the 
hydrogels to various degrees of light and exposure time. They found that by applying UV light to a 
photolabile hydrgrogel they could increase the rate of siRNA release and that by varying the exposure 
time and intensities the rates of release could be altered. They also found that UV exposure for 
different lengths of time and at different intensities did not affect the bioactivity of the released siRNA. 
Another group employed radiofrequency and critical temperatures to stimulate release by crosslinking 
N-isopropylacrylamide and acrylamide with bis-acrylamide in the presence of APS/TEMED212. Above 
certain critical temperature the hydrogels turns to liquid thereby releasing its payload. To this end 
magnetic PEG-disulphate particles and siRNA were co-encapsulated within the hydrogel, 
radiofrequency was then used to heat the particles to a temperature above the critical temperature 
resulting in gel liquidation and in turn siRNA release. Temperature controlled release has been 
achieved by entrapping polyplexes in a hydrogel composed of glycol chitosan, a water-soluble 
chitosan, and a benzaldehyde-capped tri-block copolymer of poly(ethylene oxide)-poly(propylene 
oxide)-poly(ethylene oxide)213. With these hydrogels, by varying the temperature the rate of polyplex 
release could be varied. 
 
1.5 In vivo RNAi delivery using hydrogels 
 
Evidence of the progression made from in vitro to in vivo application of RNAi based therapeutics 
harnessing hydrogel formulations for their localised, and sustained delivery is described below. siRNA 
in combination with hydrogel scaffolds has been used to treat a range of disease states including; 
cancer214–219, inflammation220–226, bone regeneration227–229, and cardiovascular disease230–232. 
 
1.5.1 Cancer  
 
Much of the research utilising hydrogels for RNAi delivery has been in cancer, most probably due to 
the large body of existing knowledge utilising siRNA as a cancer therapeutic.  
 
In earlier work, advantage was taken of the fact that the polycation chitosan (1.2.2.3.4 Chitosans) in 
conjunction with glycerol-2-phosphate undergoes a temperature driven liquid to gel transition upon 
injection in vivo214. Fluorescently labelled siRNA delivered within the chitosan hydrogel was shown to 
be localised in a tumour to a higher degree after intra-tumoral injection in a mouse relative to siRNA 
alone. Efficiency of RNAi was determined using anti-transglutimase 2 (TG2) siRNA. TG2 has been found 
to be up regulated in tumour growth233. Injection with chitosan hydrogels resulted in significant 
inhibition of tumour growth for both melanoma (48%) and breast cancer tumours (66%) relative to 
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chitosan with control siRNA. In another example of hydrogels as potential multi-therapeutics, co-
delivery with docetaxel resulted in even greater inhibition of tumour growth (72% and 92% reduction 
in melanoma and breast cancer tumours respectively). It was not clear however whether the siRNA 
was released from the chitosan hydrogel as chitosan/siRNA complexes. 
  
Another group used polyplexes to form hydrogels for siRNA release215–218. In their initial work215 PEI-
poly(organophosphazene) (PP) was used to form thermally responsive hydrogels containing cleavable 
ester-linkages. PP was formed by combining a hydrophobic isoleucine ethylester, a hydrophilic amino 
PEG (for thermosesitivity) and cationic PEI (for gene delivery). At room temperature the PP formed 
polyplexes, while at 37°C a gel was formed.  siRNA displayed a consistent pattern of release which was 
measured up to 28 days. Fluorescently labelled siRNA was used to show retention in mice tumours. 
Fluorescent signal was shown to be maintained for 21 days where as siRNA delivered alone had 
disappeared by day 7. Anti-Cyclin B1 (cell cycle regulator – the inhibition of which leads to cell cycle 
arrest) siRNA in PP hydrogel was shown to reduce tumour size after 4 weeks in vivo compared to 
controls (PBS, anti-cyclin B1 siRNA alone, and PP complexed with anti-GFP siRNA) which had no effect 
on tumour size.  
In follow up studies the group formulated PP, with a range of different polymer and drug combinations 
aimed at the long-term localised delivery of siRNA to tumours. PP was modified with a folate (FPP) to 
form targeted micelleplexes217. The addition of the folate meant that micelleplexes selectively entered 
cancer cells over expressing folate receptors. The hydrogel, acting as a depot for sustained release 
targeted siRNA complexes, was administered by subcutaneous injection so that the released 
micelleplexes could enter the circulatory and lymphatics systems. In order to determine the 
targetability of this formulation, fluorescently labelled siRNA was injected into the opposite side of 
the mouse from the tumour in the right dorsal subcutis. By imaging the mice at predetermined time 
points, using an optical imager, it was found that when injected alone the siRNA  was cleared from the 
system within a few hours, while the FPP and PP conjugated siRNA was found to be localised to the 
injection site for up to 10 days. Mice treated with FPP curiously had a reduced tumour size despite the 
fluorescent signal only being seen at the injection site. It was hypothesised that this was due to a 
relatively small amount of siRNA present in the tissue coupled with a signal which weakened overtime. 
They confirmed by dissecting the organs that the reduction in tumour size was due to the released 
micelleplexes with a significantly stronger fluorescent signal in the tumours of FPP injected mice 
compared to PP siRNA or siRNA alone treated mice. The therapeutic effect of the FPP was further 
assessed by forming micelleplexes with anti-VEGF siRNA. Mice which were treated with FPP displayed 
anti-tumour activity up to 3 weeks. Reduced VEGF expression was found only in mice treated with the 
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FPP. They also noted that once the hydrogel had fully degraded, the tumour began to increase in size. 
In order to compensate they increased the volume of injected hydrogel and reported anti-tumour 
effects were maintained for a longer period (30 days). This indicates a dose dependent effect of 
treatment and the need for a continual presence of treatment until the disease state can be cleared 
from the system completely. 
Most recently published they have developed the dual delivery of docetaxel and siRNA using a ternary 
nanocomplex hydrogel218. PP and docetaxel were conjugated via hydrophobic interactions with the 
isoleucine moiety and siRNA targeting B cell lymphoma 2 (Bcl-2) (a gene known to be involved drug 
resistance and apoptosis234) was attached via ionic interactions with PEI at 4°C to form thermosensitive 
polymer/chemical drug/gene complexes. When injected directly into the tumour or at 37°C a hydrogel 
was formed. Again uncomplexed siRNAs were released in a burst release whereas complexed siRNA 
and docetaxel displayed a more gradual pattern of release over 40 days in vitro. siRNA was present up 
to 41 days in vivo, and tumour inhibition was maintained for 4 weeks following a single injection. 
This group has also formed hydrogels from conjugating protamine CPPs to the carboxyl group of 
poly(organophosphazene) via an amide linkage without PEI216. Anti-VEGF siRNA was selected to target 
tumour growth. The group reported localisation of fluorescently labelled siRNA to the tumour site for 
24 days using their hydrogel formulation while siRNA alone was cleared completely from the site 
within 48 hours. Tumour growth after 4 weeks following a single injection, with the anti-VEGF siRNA 
containing hydrogel, was found to be inhibited, with tumour volume of less than 600 mm3 compared 
to controls which ranged from 1400 – 1000 mm3 which included an anti-GFP siRNA conjugated to their 
hydrogel formulation, anti VEGF siRNA and a PBS only control.  
 
The studies above illustrate how hydrogel-based delivery can be used to have beneficial outcomes in 
the treatment of cancers, and in particular how they can be used to localise chemotherapeutics to the 




Hydrogels have also been assessed as potential delivery vehicles for siRNA oligonucleotides targeting 
a variety of mRNA sequences involved in inflammation 220–226.  Inflammation can play a major role in 
worsening the prognosis of many diseases state rendering it an important RNAi target.  
 
Towards the treatment of inflammatory bowel disease (IBD), Laroui and colleagues220 formed 
polyplexes with PEI and anti CD98 siRNA and encapsulated them in an alginate-chitosan hydrogel 
which they crosslinked with calcium and sulfate. CD98 is an important mediator of homeostasis and 
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the innate immune response in gastrointestinal tract and has been found to be up-regulated in those 
who suffer IBD235,236. Mice were given daily doses of the formulation via oral administration. The 
hydrogel selected was pH sensitive and therefore only released its payload in the colonic lumen at a 
pH range of 5-6. Weight loss, myeloperoxidase (MPO) activity (indicator of neutrophil infiltration into 
the colonic mucosa237), CD98 and pro-inflammatory cytokines mRNA levels were all assayed to 
determine the therapeutic effect of siRNA administered in this manner in a mouse model of colonic 
inflammation. Weight loss of 10% was seen in the no treatment control groups as well as the 
nanoparticle alone groups after 8 days while only a 3% loss was seen in hydrogel containing PEI/anti-
CD98 siRNA. A fourfold reduction in MPO activity and a reduction in the mRNA levels of pro-
inflammatory cytokines keratinocytes, interleukin 1β and 6 of 50, 50 and 33% respectively were 
reported in the hydrogel PEI/anti-CD98 siRNA group and are indicative of a reduction in inflammation.  
 
A commercially available polyamidoamine dendrimer (Superfect™) was used to form polyplexes which 
were entrapped within collagen hydrogels221. pDNA was encapsulated into collagen microspheres 
which were also embedded in the collagen hydrogels with the polyplexes. Anti-interleukin-6 (IL-6) 
siRNA was co-delivered with pDNA encoding endothelial nitric oxide synthase (eNOS) (IL-6 inhibitor 
and pro-angiogenic factor) in an attempt to reduce the foreign body response seen in organs and 
transplants. Release experiments showed that release rates of the siRNA and pDNA were different, 
with the siRNA being released more rapidly (50% within 5 days) from the system compared to pDNA 
(< 20% within 5 days). This suggests potential for temporal control of delivery of the different 
components. Hydrogels were delivered via injection into the subcutaneous space prior to gelation. 
The authors reported reductions in inflammatory cells of 46 and 34% when IL-6 siRNA was delivered 
alone and in conjunction with eNOS pDNA at 7 days respectively. No significant change was reported 
when eNOS pDNA was delivered alone. At 14 days there was a significant increase in blood vessel 
density, however this was highest in groups treated with the pDNA alone which could be due to the 
more gradual release profile of the pDNA. A protein analyses was conducted on various inflammatory 
and angiogenic proteins and revealed an overall reduction in inflammatory cytokines and an increase 
of angiogenic factors expression. The results achieved here would indicate that hydrogels could be 
used, to regulate the foreign body response and promote the vascularisation of transplanted organs 
while decreasing inflammation. 
 
The beneficial effect of Hydrogels delivering RNAi molecules on inflammation in wound healing 
models has also been reported. Zhao and co-workers222 combine polyvinylpyrrolidone, polyvinyl 
alcohol, glycerol, water and siRNA (Entranster-R-coated, commercially available transfection agent), 
naked siRNA or saline in a vacuum mixer to form hydrogels which were poured into a siliconized 
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mould. The hydrogels were then transferred to medical non-woven fabric to form patches which were 
pasted onto hypertrophic scars of mice. Treatment with patches containing Entranster-R/TGFβ1-337 
siRNA lead to a significant decrease in TGFβ1, scar volume and collagen content compared to controls. 
The orientation of collagen fibres in scars treated with the Entranster-R/TGFβ1-337 siRNA hydrogel 
patches were also found to more closely resemble a healthy dermis compared to controls.  
 
Collagen type 1 which was cross-linked with 4-arm PEG with succinimidyl glutarate termini to form a 
hydrogel has also been used in a wound healing model226. miRNA-29B was incorporated into the 
hydrogel scaffold and placed on dermal wounds which had been created in rats. miRNA-29B was 
selected as it has previously been shown to; play an important role in fibrosis in many different tissues, 
to directly target fibronectin, collagen type I & III, and its down regulation or complete loss of 
expression has been observed in fibrotic tissue238–242. A significant reduction in wound contraction for 
all groups compared the no-treatment controls was reported. Rats which received 5 µg of miRNA 
displayed a significant increase in granulation tissue (highly vascularised, forms the surface for new 
tissue formation) compared to a lower dosage of 0.5 µg. A reduction in the ratio of collagen type I and 
III (an indication of stiffer, mainly type I collagen granulation tissue) was also reported for all groups, 
except the 5 µg miRNA group, compared to unwounded tissue. 
 
1.5.3 Bone Regeneration 
 
Hydrogels delivering RNAi agents have also been used to facilitate bone regeneration227–229. It has 
previously been reported that the use of hydrogel based scaffolds for bone repair has advantages over 
current treatments which include the use of metallic implants and bone grafts. These advantages 
include: they can be injected into inaccessible sites using less invasive techniques; can gel in situ and 
the fabrication of a patients specific implant is not needed as the injected gel can take the shape of 
the injury site243.  
 
Manaka et al.,228 used  poly-D,L-lactic acid-p-dioxanone- polyethylene glycol block co-polymer (PLA-
DX-PEG), a biodegradable hydrogel to deliver anti-Noggin siRNA in vivo to enhance the effect of BMPs 
(factor that promotes bone and cartilage formation). The hydrogels were formed ex vivo with siRNA 
then surgically implanted into the left dorsal muscle pouches of mice to promote ectopic bone 
formation.  Fluorescently-labelled siRNA was used to determine intracellular delivery and was found 
localised to cells adjacent to the implants. The fluorescence signal increased in a dose dependent 
manner and was significantly higher than the naked siRNA, which was delivered via direct injection 
into the muscle, however the signal decreased over time to undetectable levels at 7 days. To 
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determine the potential of ectopic bone formation due to enhanced BMP-2 presence, hydrogels 
containing recombinant human BMP-2 with and without siRNA were implanted. Two weeks post 
implantation the hydrogels had been completely replaced by new bone for both groups. They 
determined the mean size of the ossicles and calcium content, and found that the ossicles were 
significantly larger in the group of mice treated with both BMP-2 and siRNA and had significantly 
higher mineral content compared to the group which received BMP-2 alone. What is interesting to 
note about this study is the lack of cellular translocation vehicle for the siRNA. The authors suggest, 
based on previous reports, that the poly (D,L-lactide-co-glycolide), an amphipathic molecule, 
component of their hydrogel enters the cell via endocytosis through fluid-phase pinocytosis and 
escapes endo-lysosomal degradation to slowly release their contents into the cytoplasm244,245.  
 
A hydrolytically degradable hydrogel PEG-b-poly(lactide)-b-dimethacrylate (PEG-b-PLA-b-DM) has 
been used to deliver siRNA nanoparticles to promote bone fracture healing229. siRNA targeting WW 
domain-containing E3 ubiquitin protein ligase 1 (Wwp1) was selected as it has previously been 
reported that its down regulation promotes the rate of bone formation and bone mass246.  A murine 
mid-diaphyseal femur fracture model was used to assess bone repair. siRNA was complexed with a 
diblock co-polymer consisting of dimethylaminoethyl methacrylate and propylacrylic acid into 
nanoparticles before being mixed with PEG-b-PLA-b-DM and lithium arylphosphate (a photo-initiator 
of gelation). Hydrogels were crosslinked ex vivo using UV light and surgically implanted at the fracture 
site. Nanoparticles delivered via hydrogel were localised to the fracture site for 3 weeks while 
nanoparticles that were injected into the site had been cleared from the site within 3 days. In vivo 
gene silencing was determined using quantitative real time PCR. Levels of Wwp1 in fractures which 
received anti-Wwp1 siRNA delivered by hydrogels were reduced to 23% of untreated control groups. 
At the same time those genes which are associated with bone growth were also upregulated including 
osteocalcin, collagen type 1 and alkaline phosphatase. Fracture healing was assessed by the presence 
of calcified bone callus. Calcified calluses were reported in 11 out of 12 mice treated with anti-Wwp1 
siRNA nanoparticle hydrogels 3 weeks post treatment (compared to 6 out of 12 for the control), while 
one out of 12 untreated mice displayed evidence for callus formation. Histological analysis confirmed 
accelerated fracture healing in treatment groups compared to the no treatment control groups. Callus 
area and cartilage formation was increased in the treatment group at 14 days and by 21 days had 
significantly less unimineralised cartilage and larger bone area relative to the untreated control 
groups.  
 
These studies illustrate the potential for using degradable hydrogels to deliver siRNA in order to 
promote bone growth and healing however, gels in both studies were formed ex vivo and implanted. 
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Since the gels were surgically implanted the potential benefits of the gel taking the form of the injured 
area were not realised or examined. Photocrosslinking hydrogels ex vivo, followed by surgical 
implantation or for that matter injecting hydrogels and photocrosslinking in vivo are not always viable 
options in area of bone that are hard to reach. Further research using in situ forming hydrogels not 
dependent on photocrosslinking may hold great potential in this area. 
 
1.5.4 Cardiovascular Disease 
 
Hydrogel based delivery of RNAi therapeutics have also been used towards the treatment of 
cardiovascular disease230–232. Pullulan, a naturally occurring polysaccharide that is considered 
nontoxic, non-immunogenic and is biodegradable was used to coat carotid stents to prevent 
restenosis – a complication of coronary stent implantation – via inhibition of MMP2230. Elevated levels 
of MMP2 have previously been associated with increased restenosis247.  Pullulan was functionalised 
by grafting of diethylaminoethylamine groups to form a cationised pullulan hydrogel that would be 
able to complex with siRNA via electrostatic interactions to form nanoparticles. The hydrogels were 
physically crosslinked with sodium trimetaphosphate. Kinetic studies were conducted to determine 
siRNA retention and found that 20% of siRNA was released from the cationic pullulan after 1 hour, 
whereas the neutral pullulan stents eluted 100% of siRNA in less than 10 minutes. For in vivo 
experiments, a balloon catheter was used to induce right carotid abrasion in a rabbit model. The 
cationised pullulan hydrogel coated stents were then implanted 15 days post injury. Using Tamra-
tagged siRNA, they were able to show siRNA internalisation in the carotid artery 24 hours after 
implantations, and silencing of MMP2 was reported (approximately 28%). Functional outcomes such 
as arterial flow were either not assessed or not reported on. 
 
For the delivery of siRNA into the myocardium, PEI (section 1.2.2.3.5) has been modified in order to 
fulfil the dual role of as a transfection agent and as a component of the hydrogel232. PEI was modified 
with β-cyclodextrin (CD) and triethylamine to form CD-PEI. An 8-arm PEG-maleimide was modified by 
reacting it with 1-adamantanethiol via Michael addition to form Ad-PEG. Hydrogels could form 
through guest-host interactions between CD and adamantane. To encapsulate the siRNA, polymers 
were mixed with the siRNA to form polyplexes which at higher concentrations formed shear thinning 
hydrogels through a guest-host interaction. Sustained release of siRNA was observed from the 
siRNA/CD-PEI/Ad-PEG system at a constant rate over a two week period (less than 10%). Hydrogels 
containing fluorescently labelled siRNA were injected into the left ventricle of rats which were 
sacrificed after 24 hours to determine localisation. The fluorescent signal was localised to the site of 
injection. GFP expressing rats were used to determine efficacy of siRNA delivered from within this 
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hydrogel system. Rats were injected with the hydrogel formulations containing either an anti-GFP 
siRNA or a negative control siRNA into the left ventricular wall and were sacrificed 24 hours or 7 days 
post injection. In rats sacrificed 24 hours post inject a 40% drop in GFP expression was reported and 
this reduction was maintained for 1 week.   
 
In another study, targeting fibrosis in the ECM, miRNA-29B was incorporated into hyaluronic acid 
which was modified with thiols and cross-linked with PEG diacrylate to form a hydrogel248. Their 
hydrogel, which is polymerised in 20 minutes at room temperature, was injected into the peri-infarct 
zone of mice that had undergone left anterior descending artery ligation. miRNA-29B was selected for 
delivery as its down regulation in the peri-infarct zone has previously been shown to contribute to 
fibrosis242. Myocardial function was tested at 2 and 5 weeks post infarct and significant improvement 
was recorded for ejection fraction at both time points relative to control mice which received a 
scrambled miRNA sequence. A significant improvement in fractional shortening and fractional area 
change was also reported at the 5 week time point compared to the scrambled control group. No 
significant difference in scar size was reported for either group. However, a significant reduction in 
elastin expression in the peri-infarct zone and a trend towards increased vascularisation in both the 
peri-infarct zone and the centre of the infarct in mice treated with the miRNA29B relative to controls 
was reported.   
 
The above studies demonstrate the feasibility of delivering RNAi molecules via a hydrogel system to 
achieve a therapeutic outcome via sustained localised delivery. This potential has been illustrated by 
anti-tumorigenic effects, mediation of inflammation, and improved bone healing and cardiac 
outcomes in vivo. They have also been shown to have beneficial outcomes in wound healing 
experiments demonstrating improved scar healing222,226. This highlights the scope of applications 
possible using a hydrogel system in this manner. As well as being able to both sterically and covalently 
entrap nanoparticles, hydrogels can also have cell adhesion sites allowing for cell migration and 
entrapment and can be used to co-deliver other therapeutics. 
 
1.6 Enzymatically degradable hydrogels 
 
Enzymatically degradable hydrogels which have the ability to form crosslinks spontaneously without 
the need of an external light source have the potential to allow for delivery of RNAi oligonucleotides 
in scaffolds that are injectable and permit cell based release of siRNA. A synthetic peptide cross-linked 
hydrogel based system (poly(ethylene glycol) (PEG)) is one such hydrogel option. The potential and 
versatility of using these types of PEG hydrogels is discussed below.  




PEG hydrogels have been designed to have the ability to form spontaneously at physiological 
temperature and pH via Michael type addition reaction without the formation of by-products249. A 
Michael addition reaction is a nucleophilic reaction whereby a nucleophile is added onto unsaturated 
esters250. Briefly, PEG monomers with branched structures can be constructed with vinyl sulfones at 
their termini. Vinyl sulfones are able to very specifically covalently bind to thiols via the Michael 
addition reaction251. Thus these branched PEG molecules can be cross-linked with any molecule 
containing at least two thiol moieties 203,251.  As a consequence thereof, a peptide containing two 
cysteine residues when added stoichiometrically to a PEG vinyl sulfone mixture can cause 
polymerisation of the hydrogel. Furthermore, the peptide sequence can be synthesised such that they 
contain proteolytic recognition sequences201. With the incorporation of such peptides as crosslinkers, 
the hydrogel becomes enzymatically degradable and can regulate cellular ingrowth to be dependent 
on cellular based proteolysis201–203.  
 
These types of hydrogels have shown utility in a range of therapeutic areas inclusive of bone 
growth201,252, angiogenesis197 and myocardial infarction253–255. Bone formation was enhanced in a rat 
cranial model by the sustained delivery of BMP-2. Increased blood vessel growth was found in 
hydrogels containing covalently linked VEGF and importantly release of VEGF was found to be 
contingent on cellular invasion. Cellular invasion and migration was also shown to be dependent on 
the presence of cellular adhesion peptides such as RGD that were attached covalently through 
cysteine residues201,202. The rate of cellular invasion can also be controlled in these hydrogels, both in 
vitro and in vivo by simple titration of the degradability of the peptide crosslinking sequences203.  
 
Our group has investigated the ability of these hydrogels to biomechanically support the infarcted 
heart after cardiac injection253,254. The delivery of the hydrogel was shown to reduce wall thinning in 
the infarcted wall of the heart, thus reducing the mechanical stress experienced by surviving 
cardiomyocytes. This was found to result in reduced functional damage. Though, these findings are 
promising, they are not sufficient as a therapy for infarction, and the delivery of bioactive modalities 
has begun to be assessed. Importantly for the work described in this thesis, the PEG hydrogels were 
shown to be able to entrap and localise growth factor containing microspheres in the infarcted rat 
heart255. Coacervates of heparin and poly(ethylene argininylaspartate digylceride) were formed that 
contained the factors Sonic Hedgehog and IL-10 that were approximately 1 µm in diameter. These 
coacervates were sterically entrapped and the combination of coacervates and hydrogel were found 
to improve the functional outcome in infarcted rat hearts relative to the individual components.  
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For the in vivo studies highlighted above 8-arm PEG hydrogels were used while in vitro studies have 
also been conducted, for which a 4-arm PEG hydrogel was employed202,203,253–255. The in vitro studies 
demonstrated how cellular ingrowth in the hydrogel could be controlled by varying peptide crosslinker 
used to polymerise the gel202,203. Regulation of tissue ingrowth was also demonstrated in vivo by 
surgically implanting PEG hydrogels, polymerised within highly porous polyurethane discs, 
subcutaneously in a rat203. 
 
Thus these enzymatically degradable hydrogels have shown potential in a variety of therapeutic 
arenas and are able to sterically entrap microspheres that contain bioactive agents. This could also be 
exploited to entrap nanoparticles containing siRNA conjugates. The work in this thesis describes the 
initial experiments directed towards their further exploitation as RNAi molecule delivery vehicles. 
 
It is hypothesised that the entrapment of PEI/siRNA nanoparticles within PEG hydrogels will allow for 





The fundamental aim of this project is to assess the potential of using a PEG hydrogel to localise 
delivery of PEI/siRNA nanoparticles.  Enzymatically degradable PEG hydrogels have previously been 
shown to allow cellular invasion and have been used as depots for the controlled release of a variety 
of drugs and proteins. PEI was selected for entrapment within the enzymatically degradable PEG 
hydrogel as it is considered a gold standard for nanoparticle based delivery of siRNA. .  
 
A prerequisite is the establishment of the required techniques for PEI/siRNA nanoparticle formation 
and optimisation in our laboratory. To achieve maximum transfection a nanoparticle formulation 
needs to meet certain criteria listed below. Nanoparticles or polyplexes are formed based on a ratio 
between amine nitrogen’s of the PEI to the phosphates of the siRNA (N:P ratio). It is necessary to assay 
a range of these ratios for complexation, stability, cytotoxicity, and transfection capability.  
 
Prior to assessing the efficacy of hydrogel based delivery of RNAi therapeutics in vivo, it is necessary 
to optimise and characterise aspects such as the release and bioactivity of entrapped nanoparticles in 
in vitro models that resemble the in vivo scenarios as closely as possible.   
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A secondary aim of this project is the establishment of an in vitro RNase protection assay for 
encapsulated nanoparticles. siRNA oligonucleotides are subject to degradation by RNases present 
both in vitro and in vivo. PEI nanoparticles are widely reported to protect their siRNA cargo from 
RNases. The influence of PEG encapsulation on PEI based RNase protection still requires assessment.  
 
These hydrogels are enzymatically degradable, and thus allow for cell-directed invasion. Upon 
implantation, these hydrogels will be invaded by cells from surrounding tissue and it is therefore 
necessary to develop a 3D RNAi assay which properly mimics this in vivo environment. A variety of 
cellular entrapment techniques will be assayed for entrapment and invasion potential.   
 
The objectives of this project can be summarised as follows: 
 
1. Determine the optimal ratio of PEI to siRNA (N:P) for delivery of siRNA in terms of: 
 Complexation 
 Stability  
 Cytotoxicity 
 Transfection  
2. Entrapment and release of nanoparticle formulation within PEG hydrogels 
 Influence of 3D encapsulation on RNase degradation 
3. Development of a 3D cellular invasion assay for the assessment of siRNA delivery in vitro 
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2. Materials and Methods 
 
A detailed list of all reagents and equipment used can be found in Tables A1.1 – A1.3 of the Appendix 
(section A1). The recipes and other instructions for buffers and other reagents which are commonly 
used can be found in section A2 of the Appendix, Tables A2.1 – A2.4.  
 
2.1 Tissue Culture 
 
HT1080 cells were used for all tissue culture experiments. HT1080 cells are a fibrosarcoma line from a 
35 year old human male. Cells were never used above passage 20 (P20). All tissue culture related work 
was conducted in a Bio-Hazard Laminar Flow Hood. All surfaces and containers entering the hoods 
were first sprayed and wiped down with 70% ethanol. 
 
Prior to working in tissue culture with cells, MCDB-131 or Dulbecco’s Modified Eagle’s Medium 
(DMEM) media was prepared. Before working with cells, MCDB-131 or DMEM, Foetal Bovine Serum 
(FBS) and Penicillin / Streptomycin (P/S) was removed from 4˚C fridge and allowed to warm to room 
temperature on the bench or in a 37°C water bath. Media containing FBS was prepared fresh on the 
day of use in 50 ml Falcon® tubes. FBS was added at a concentration of 10% (v/v) while P/S was added 
to a concentration of 1% (v/v) (100 U penicillin/ml and 100 µg streptomycin/ml). P/S was added to all 
media involved with the routine passaging and thawing of cells, however, it was not present in 
experiments involving cells. 
 
2.1.1 Thawing of Cells 
 
Cells were removed from cryostorage, thawed at room temperature and the contents added to a T75 
cm2 or a T25 cm2 flask containing 12 ml or 5 ml 20% (v/v) FBS media respectively. Cells were seeded 
at a maximum density of 20 000 and a minimum density of 6500 cells per cm2. The flask was then 
placed in the 37°C, 5% CO2 incubator overnight after which time the media was replaced with fresh 
10% media. 
 
2.1.2 Passaging of Cells 
 
When cells were 70 - 90% confluent they were passaged. The media was removed and discarded and 
cells washed 2X with 5 to 8 ml iso-PBS. The washed cells were then incubated with 5 ml of trypsin in 
the 37°C, 5% CO2 incubator. Once the cells were detached the trypsin was deactivated with 5 ml 
MCDB-131, 20% FBS media. The solution containing the detached cells, media and trypsin was then 
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pipetted into a 50 ml Falcon® tube and centrifuged for 3 minutes at 1 500 revolutions per minute 
(RPM). After centrifugation was complete, and the presence of a pellet confirmed, the supernatant 
was carefully discarded. The cells were resuspended in 1 ml MCDB-131 or DMEM, 10% FBS media. 
Between one fifth and half of the solution of media containing cells was added to a new flask 
containing media. 
 
2.1.2.1 Cell Counting 
 
For all experiments involving cells as well as cryopreservation, the cells were counted using a 
haemocytometer. To count the cells, 20 µl of the resuspended cell solution from section 2.1.2 was 
added to 20 µl Trypan Blue (0.4% m/v). The haemocytometer and cover slip were cleaned with 70% 
ethanol before adding 10 µl of the cell Trypan blue mixture directly under the cover slip. Grids 1, 2, 4 
and 5 were counted, averaged and the number of cells per millilitre was determined as follows:     
 
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑 ×  2 × 10′000 = 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑚𝑖𝑙𝑙𝑖𝑙𝑖𝑡𝑟𝑒  
 
2.1.3 Cryopreservation of Cells 
 
Stocks of HT1080 cells were cryopreserved. Cells were counted according to the above method 
(section 2.1.2.1) and frozen in stocks of 500 000 cells per vial. A volume of Media, 10% FBS containing 
500 000 cells was added to 2 or 1.5 ml cryostorage tubes and placed on ice. To maintain cellular 
integrity cells were frozen in 7.5% (v/v) dimethyl sulfoxide (DMSO). An equal volume of MCDB-131, 
10% FBS and 15% DMSO was then added drop wise to media containing cells and placed on ice. Cells 
were frozen overnight at -65°C in a polystyrene rack before being transferred to liquid nitrogen (-
196°C) for long term storage. 
 
2.2 siRNA/PEI Nanoparticle preparation 
  
Nanoparticles were formed at a range of ratios and in varying concentrations, buffers and solutions 




Various siRNA sequences with and without fluorescent tags were used to form nanoparticles (Table 
1). The type of siRNA used to form complexes was based on experimental requirements.  
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siRNAs arrived lyophilised from the respective suppliers and re-suspended in RNase free water which 
arrived with the siRNA. The siRNA was re-suspended to 100 µM and 20 µl aliquots were made and 
stored at - 20˚C. 
 
Table 1: Summary table of the different siRNAs used to form nanoparticles complexes in this project.   
Product name Modification Molecular Weight 
AllStars Negative 
Control siRNA 
AF 488 15 550.9 g/mol 
AllStars Negative 
Control siRNA 
AF 555 16107.1 g/mol 
AllStars Hs Death 
Control siRNA 
- 13 295.1 g/mol 
Negative control 
siRNA 
- 13299.9 g/mol 
*AF = Alexa Fluor 
 
2.2.2 Complex formation 
 
Nanoparticle complexes were initially formed at a range of nitrogen to phosphate (N:P) ratios in order 
to determine which was optimal for siRNA delivery. The ratio is determined by the nitrogen within the 
PEI and the phosphate within the siRNA. PEI stocks of 4.3 mg/ml (0.172 mM PEI) were prepared in iso-
PBS. A 0.172 mM solution of PEI is equivalent to 0.1 M nitrogen (100 nmol amine nitrogen per 
microliter)256 while there are 3 nmol phosphate per microgram of siRNA256. This solution was then 
filter sterilised with a 0.20 µm syringe filter unit.   
 
Nanoparticles were formed at N:P ratios of 0:1, 1.25:1, 5:1, 2.5:1, 5:1, 10:1, 20:1 and 40:1 in 20 µl 
solution as detailed in Table 2. After the addition of all the components, samples were incubated for 
30 minutes at room temperature to allow for complex formation. Prior to each experiment a master 
mix of nanoparticles was made from which technical repeats were derived. Nanoparticles were always 
formed according to this protocol unless otherwise stated. 
  
Table 2: Volumes according to which a single aliquot of nanoparticles of various N;P ratios were prepared.   
  Ratios 
N:P 
Stock solution Volume (µl) 
PEI (µM) siRNA (µM) siRNA PEI Diluent 
0: 1 0.0 1.5 10 0 10 
1.25: 1 0.172 1.5 10 7.5 2.5 
5:1 1.72 1.5 10 3.00 7.00 
10:1 1.72 1.5 10 6.00 4.00 
20:1 17.2 1.5 10 1.20 8.80 
40:1 17.2 1.5 10 2.40 7.60 
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2.3 Assessment of Nanoparticle Formation 
 
The optimal N:P ratio was determined by gel retardation, RNase protection, transfection efficacy and 
cytotoxicity assays. 
 
2.3.1 Gel Retardation Assay – Agarose Gel Electrophoresis 
 
This assay allows for the assessment of complex formation. The complexes were formed at a 
concentration of 0.75 µM siRNA in 20 µl NanoPure Water. A 4% agarose gel was made using 0.5X TBE 
buffer (Appendix A2). After complexation, 5 µl GoTaq Green containing GelRed nucleic acid stain was 
added to the samples and vortexed. Following vortexing, 12.5 µl (7.5 pmols) of the sample mix was 
loaded into the wells of an agarose gel. The gel was run at 80V constant for 30 – 35 minutes. The gel 
was visualised and quantified using an InGenuis3 gel documentation system & GeneSys image capture 
and GeneTools image analysis software. All quantification was conducted on raw images taken on the 
InGenuis 3. Any adjustments to band intensities were done to the entire gel image. For purposes of 
presenting the images in figures, empty lanes were removed. 
 
2.4 Complex Stability Assays 
 
In order to determine the stability of the nanoparticles and therefore their ability to protect the siRNA, 
they were exposed to RNases which are present in FBS257. 
 
2.4.1 Protection of siRNA from RNase present in Foetal Bovine Serum (FBS)22,258,259 
 
After nanoparticle formation, an equal volume of FBS was added to each ratio sample so that the final 
concentration of FBS was 50%. Samples were kept at 37°C. At time points T = 1, 3, 6, 24, 72, 120 and 
168 hours 20 µl of sample was removed and added to 5µl 2.5% SDS (0.5% final) and flash frozen in 
liquid nitrogen before being stored at -65°C. The SDS dissociates the nanoparticles and neutralises 
RNases present in the solution and was added to all samples including controls. Naked siRNA and 50% 
FBS served as controls and were frozen with SDS until the completion of the experiment.  
 
Once all samples had been taken, the samples, including controls, were defrosted and subjected to 
gel electrophoresis (section 2.3.1). The results were quantified using GeneTools image analysis 
software and normalised to the naked siRNA control. 
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2.5 Cellular Transfection of siRNA 
 
Unless otherwise stated, cells were seeded in a clear flat bottomed 96-well plate that was tissue 
culture treated and sterile, at a concentration of 6 000 cells per well in 200 µl, 10% MCDB-131 media 
and incubated overnight at 37°C. Cells were always seeded in the centrally located wells of the plate 
and not on the edge. This was done to avoid any variations in seeded cells due to evaporation in the 
outer wells, media or PBS alone was aliquoted into these wells instead. After overnight incubation 
nanoparticles were prepared for transfection experiments as described below. 
 
2.5.1 siRNA transfection of cells 
 
Cells were seeded a minimum of 24 hours prior to the commencement of the experiment. After 24 
hours each well was viewed under a light microscope to determine if the cells were evenly seeded and 
of similar density in all of the wells.  
 
After nanoparticle formation, each sample was diluted 1:5 in 10% FBS containing media and vortexed. 
The media was removed from the cells and the cells washed 1X with iso-PBS which was then replaced 
with 100 µl of each nanoparticles ratio. Samples were well mixed by pipetting up and down before 
being added to the cells. Each well then received an additional 100 µl media and placed in the 37˚C, 
5% CO2 incubator for 4 hours, occasionally shaking. After 4 hours had elapsed, media was removed 
and the cells washed 1X with iso-PBS before being replaced with 200 µl media. The cells were then 




The efficacy of internalised siRNA as well as the cytotoxicity of PEI/siRNA nanoparticles was assayed 
using CellTiter-Glo® from Promega. The commercially available CellTiter-Glo® enables the user to 
determine cell viability by reacting with the ATP present in metabolically active cells. The addition of 
the CellTiter-Glo® reagents causes cell lysis and the release of ATP which reacts with luciferase to give 
a luminescent signal. Briefly, luciferin undergoes mono-oxigenation, a reaction which is catalysed by 
luciferase (in this case a proprietary thermostable luciferase – Ultra-Glo™ Recombinant Luciferase) in 
the presents of magnesium, ATP, and molecular oxygen to form the light generating oxiluciferin and 
other reaction products. This cell viability assay therefore can give you an indication of the number of 
viable cells present260,261.  
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Both efficacy and cytotoxicity can be determined using this assay. Efficacy of delivered siRNA can be 
determined by using AllStars Hs Cell Death Control siRNA when formulating nanoparticles while 
cytotoxicity can determined by complexing negative control siRNA. 
 
After thawing the CellTitre-Glo® reagents, CellTitre-Glo® Buffer was added to CellTitre-Glo® Substrate 
according to the manufacturer’s specifications. An equal volume of reagent to media was then added 
to each well after which the plate was placed on an orbital shaker for 3 minutes to induce cell lysis. 
The plate was then incubated at room temperature to allow the luminescence signal to stabilise. After 
this 180 µl was removed from each well and placed in a corresponding well on an opaque, non-sterile, 
96-well flat-bottomed plate. The tips were discarded and replaced between triplicates. Wells with 
media alone were used as blanks with CellTitre-Glo® reagent. The luminescence signal was then 
recorded using a luminometer which had the conditions for the CellTitre-Glo® installed. 
 
2.5.1.2 Standard curve for determining number of cells 
 
For every experiment in which Cell Titer Glo® was used, a standard curve was also constructed on the 
same day that the experiment was seeded. After cells had been seeded on the experimental 96-well 
plate, cells from the same flask were also seeded for a standard curve. This was done in triplicate, on 
an opaque, non-sterile, 96-well flat-bottomed plate. Cells were seeded from 0 to 40 000 cells per well 
in increments of 5000 cells, in 100 µl media. CellTitre-Glo® was then added according to the protocol 
in section 2.5.1.1. 
 
2.5.2 Cytotoxicity and eficacy assay using CellTiter-Glo® Luminescent Cell Viability 
Assay 
 
2.5.2.1 Cytotoxicity of PEI/siRNA nanoparticles 
 
Cytotoxicity experiments were conducted. Nanoparticles were prepared using Negative Control siRNA 
as per section 2.5.1. Cytotoxicity and efficacy experiments were conducted in parallel. Therefore, cells 
used for this experiment were seeded on the same plate as those cells used for the efficacy experiment 
(section 2.5.2.2) with the same procedures followed.  
 
2.5.2.2 Efficacy of internalised siRNA  
 
PEI/siRNA (AllStars Hs Cell Death Control siRNA) nanoparticles were added to cells as per section 2.5.1 
siRNA transfection. After removal of the nanoparticle containing media, the 96-well plate was then 
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returned to the 37˚C incubator for 48 hours as recommend by the manufacturers of the Cell Death 
siRNA. After 48 hours had elapsed, CellTiter Glo® assay was performed (section 2.5.1.1). 
 
2.6 Zeta sizing and Zeta Potential Measurements 
 
Nanoparticles were prepared as above in section 2.2.2 Complex formation in 1 ml. Both Zeta Potential 
measurements and size measurements were taken using a Folded Capillary Cell. Negative Control 
siRNA was used to form 1 ml of 20:1 PEI/siRNA nanoparticles. To form the nanoparticles, 500 µl DEPC 
treated H2O containing 10 µg siRNA was added to 500 µl DEPC treated H2O containing 600 nmols of 
PEI amine nitrogen. The final volume was therefore 1 ml (0.75 µM siRNA).   
 
Readings were taken using the Zeta Sizer Nano ZS. Mark Houwink parameters were used to determine 
the complex size and laser Doppler anemometry with the Smoulchowski model was used to estimate 
zeta potential. 
 
2.7 Maximal concentration for nanoparticle formation 
 
Nanoparticles are formed on the basis of a molar ratio of nitrogen in the PEI to the phosphate in siRNA. 
While the molar ratio of nitrogen to phosphate remains constant, the concentration of nanoparticles 
per volume of solution can be altered to suit a given need. Due to concerns about the potential of 
nanoparticles to aggregate at higher concentrations a series of experiments was conducted to 
determine the maximal concentration of siRNA at which to form nanoparticles for an N:P ratio of 20:1. 
 
2.7.1 Cytotoxicity and efficacy 
 
The procedures followed in section 2.5.2 were used to assess the effect of increasing siRNA 
concentrations on nanoparticle efficacy and cytotoxicity.  Formation of nanoparticles at the following 
concentrations of siRNA were assessed: 0.75, 1.5, 2.0, 3.0 and 7.5 µM siRNA. Transfection was carried 
out 0.075 µM siRNA final concentration. 
 
2.7.2 Heparin Dissociation assay 
 
The stability of complexes formed at a range of concentrations was determined by a heparin 
dissociation assay. Heparin can compete with the siRNA to bind to PEI resulting in complex 
dissociation. Heparin sodium stocks were made to a concentration of 5000 U/ml in DEPC treated H2O. 
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The stocks were then diluted to 50 U/ml (0.05 U/µl) in iso-PBS. The various concentrations of siRNA 
were exposed to 0, 1, 2, 3, 4 and 5 U/ml heparin in triplicate.  
 
Fluorescently labelled (Alexa Fluor® 488) siRNA was used to form 20:1 nanoparticles at the range of 
concentrations of siRNA described above (section 2.7.1), samples were aliquoted into an opaque flat-
bottom 96-well plate. The samples were then further diluted with iso-PBS before heparin sodium was 
added to each concentration for a final volume of 100 µl. Although the complexes were formed at 
various concentrations the final concentrations in the wells was 0.15 µM siRNA. The samples in the 
wells were then mixed by shaking the plate for a minute before incubating for 10 minutes at room 
temperature. The fluorescence signal was then read at an excitation of 499 nm and emission of 519 
nm using a fluorometer. A graph of relative fluorescent units versus the heparin concentration was 
plotted. 
 
2.8 Hydrogel preparation 
 
Polyethylene Glycol (PEG) (Mw: 20 KDa) hydrogels of varying percentages (m/v) were prepared using 
both 4-arm and 8-arm PEGs. Collagen gels (2 mg/ml) were also used in this project.  
 
2.8.1 Poly(ethylene) Glycol preparation 
 
Both 4-arm (20PEG-4VS) and 8-arm (20PEG-8VS) PEG monomers (Mw: 20 KDa) with vinyl sulfone (VS) 
termini were formed as previously described251 by the polymer laboratory of the Cardiovascular 
Research Unit, UCT. Briefly, 20PEG-4VS and 20PEG-8VS were fabricated in dry Dichloromethane by 
deprotonating 20PEG-4OH and 20PEG-8OH using sodium hydride (NaH). Divinyl sulfone (C4H6O2S) was 
next added in excess. Acetic acid (CH3COOH) was used to quench the remaining NaH in the crude 
reaction mixture followed by three consecutive precipitations in ether. 
 
Vinyl sulfones react with sulfhydryls via a Michael addition reaction. Thus if divalent sulfhydryl 
containing molecules are reacted with multivalent PEG-VS at stoichiometric amounts of sulfhydryls to 
VS termini, a hydrogel is formed. A matrix metalloproteinase 1 (MMP-1) recognition sequence 
containing cysteine residues (GCREGPQGIWGQERCG, 1732.91 Da) can thus be used to polymerise 
PEG-VS hydrogels. These MMP-1 peptide sequences are enzymatically cleavable by MMP-1 and other 
members of the MMP family202. Additionally, when cell adherence was required, an Arginine-Glycine-
Aspartate (RGD) (GCGYGRGDSPG, 1025 Da) amino acid sequence containing a single cysteine residue 
was covalently bound to the hydrogel. RGD is a tripeptide which enables cell migration through cellular 
binding via integrin’s262. 




The MMP-1 peptide and PEG were combined at a molar ratio of 4:1 (8-arm) or 2:1 (4-arm) MMP:PEG. 
For cellular experiments, RGD was added prior to the addition of other gel components at a molar 
ratio of 12.5:1, PEG:RGD. The RGD and PEG were incubated for 30 minutes in a water bath at 37°C 
prior to adding other components. These were then combined to form hydrogels with a final PEG 
concentration of 2, 3.5 or 4% (m/v).  
 
The MMP-1 peptide sequence, RGD and PEG were both resuspended using triethanolamine (TEOA 0.3 
M). The gels were made up to their final volumes using TEOA in order to have the correct final 
concentration of components before the addition of the MMP-1 peptide cross linker.  An example of 
a 3.5% (m/v) 20PEG-8VS hydrogel and 20PEG-4VS hydrogel is given below (Table 3). When 
nanoparticles were added, they were added in the place of a portion of the TEOA. 
 
Table 3: Components for a 3.5%, 100 ul hydrogel for both 4- and 8-arm PEGs. 
  20PEG-8VS 20PEG-4VS 
Sequence Components  Volume Final 
concentration  
 Volume  Final 
concentration 
1 PEG 20% (m/v) 17.5 µl 1.75 mM 17.5 µl 1.75 mM 
2 RGD (0.1 
mg/60 µl) 
8.61 µl 0.14 mM 8.61 µl 0.14 mM 
3 TEOA or iso-
PBS 




28.87 µl 7 mM 14.44 µl 3.5 mM 
 
2.8.2 Collagen Gel Preparation 
 
Collagen gels were formed at a concentration 2 mg/ml using collagen derived from bovine skin or rat 
tail. When working with collagen it is important to work on ice at all times, as such all microcentrifuge 
tubes used as well as reagents were kept on ice. To make 800 µl of 2 mg/ml collagen gel, 533.34 µl of 
3 mg/ml stock solution was combine with 45.25 µl 10 X DMEM (pH 7.4), 45.25 µl of a 23 mg/ml stock 
solution of NaHCO3, 15.5 µl 0.36 M NaOH (occasionally additional NaOH was required), and finally 
160.66 µl of 1 X DMEM (pH 10, 2.3 mg/ml NaHCO3). Table A2.2 (Appendix A2) is a list of reagents used 
for collagen hydrogels and their preparation. Gels were allowed to polymerise for 30-45 minutes at 
37°C. 
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The reagents were added sequentially ending with the NaOH. In order for the gels to be able to set, 
the final solution needed to have a red to pink colour – this colour (derived from phenol red present 
in the DMEM) indicates a pH between 7.5 and 8.0. At lower pH values gelation would not occur.  
 
2.8.2.1 Dermal equivalent preparation 
 
Collagen gels were prepared according to the above protocol (section 2.8.2). Gels were prepared with 
40 000 cells entrapped per 40 µl collagen gel (1000 cells/µl). A volume of media containing the 
required number of cells was removed and placed in a 1.5 ml microcentrifuge tube and spun down 
into a pellet at 13200 rpm. Excess media was removed and replaced with the required volume of 
collagen (2 mg/ml) mix. The collagen cell solution was mixed thoroughly by pipetting and then 
aliquoted (40 µl) onto siliconized sterile petri dishes (3 cm) and allowed to set. Once set, 3 ml media 
was added to the petri dish and gels were detached from the surface using a sterile spatula. Using the 
same spatula the gels were moved into individual wells of a 24-well plate containing 10% DMEM and 
incubated for 48-72 hours at 37°C, 5% CO2. These form dermal equivalents which are used in 
experiments described below (section 2.10.2). 
 
2.9 Entrapment of nanoparticles within PEG hydrogels 
 
Nanoparticles were formed at an N:P ratio of 20:1 (2 µM siRNA) and encapsulated within PEG 
hydrogels. The nanoparticles were added to the hydrogel mixture prior to polymerisation, samples 
were vortexed before aliquoting out 20 or 50 µl gels in a siliconised (Appendix A3) 24-well plate or 
surface or on Parafilm® within a petri dish and allowed to polymerise at 37°C. To compensate for the 
addition of nanoparticles an equivalent volume of TEOA was not added to the mixture. 
 
2.9.1 Visualisation of encapsulated nanoparticles 
  
Nanoparticles were formed using AllStars Negative Control siRNA which had been fluorescently tagged 
with an Alexa Fluor® 555 label. The fluorescent tag of the siRNA allowed for the visualisation of the 
entrapped particles. The final concentration of the siRNA within the hydrogel after entrapment was 
0.75 µM.  
 
The hydrogels were imaged and z-stacks taken using a Zeiss 510 LSM Meta with a solid state laser 
(excitation: 561 nm, emission: 500-550 nm) at 10X times objective magnification, 1X zoom. 
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2.9.2 RNase protection of entrapped nanoparticles 
 
Nanoparticles were complexed using negative control siRNA. Nanoparticles were entrapped within a 
20 µl 4% 8-arm PEG hydrogel at a final siRNA concentration of 0.75 µM siRNA. All gel and nanoparticle 
preparation was done in a Bio-hazard laminar flow hood using sterile buffers and consumables.   
After the gels had set they were carefully removed (using a thin sterile spatula) from sterile Parafilm® 
and added to individual sterile 2 ml microcentrifuge tubes with 300 µl 50% FBS. These gels were then 
placed in a shaking 37°C incubator (50 rpm). For time point T0 the gels were not placed in FBS and 
frozen straight away. At T = 24, 72, 120 and 168 hours gels were removed from the 37°C incubator. At 
all-time points, including T0, gels were washed 1X using DEPC treated H2O and flash frozen in liquid 
nitrogen before being placed in the -65°C freezer for storage so that no further degradation could take 
place. As an additional control 2 gels were also placed in 300 µl DEPC treated H2O and incubated for 7 
days. Non-encapusulated PEI/siRNA were processed as above in section 2.4.1. 
 
The gels were thawed and then digested in 1 mg/ml proteinase K (10 mM pH 7.3 Tris-Cl, 1 mM CaCl2) 
and 0.5% SDS (to dissociate nanoparticles) for 2 hours in a shaking 37°C incubator. The non-entrapped 
nanoparticle complexes in FBS were also treated with Proteinase K in the same way as the hydrogels. 
Agarose gel electrophoresis was used to analyse samples (2.3 pmols) as described above (section 
2.3.1). The digested product from the T0 time point was always run alongside experimental samples 
and used as the 100% mark for quantification purposes.  
 
2.9.3 PEI/siRNA nanoparticle and naked siRNA controlled release 
 
Both PEI/siRNA nanoparticles and naked siRNA were entrapped within 4- and 8-arm 3.5% PEG 
hydrogels (section 2.8.1 and 2.9.2). Negative control siRNA was used to form nanoparticles (2 µM 
siRNA. The final concentration of siRNA for both complexed and non-complexed siRNA in the PEG 
hydrogels was 0.75 µM. 
 
Polymerised hydrogels were removed from sterile Parafilm® (using a thin sterile / clean spatula) and 
placed in individual sterile 2 ml microcentrifuge tubes containing either nothing or 100 µl HBS elution 
buffer (25 mM, pH 7.4-7.5). The hydrogels placed in the empty microcentrifuge tubes were 
immediately frozen along with the extra nanoparticles and naked siRNA solutions which were 
prepared and stored at -65°C. The gels in elution buffer were placed in a shaking (50 rpm) 37°C 
incubator and washed for 1 hour (Time = 1 hour). After 1 hour incubation, they were removed and 
placed into new sterile 2 ml microcentrifuge tubes also containing fresh 100 µl 25 mM HBS elution 
Materials and Methods   
48 
 
buffer. The Time = 1 hour microcentrifuge tube containing buffer was stored at -65°C. The process of 
moving the hydrogels, placing into fresh HBS and storing the elution buffer at -65°C was repeated at 
T = 24, 72, 120 and 168 hours. The hydrogels were placed in the initial “wash” buffer for one hour to 
remove any nanoparticles and siRNA which are perhaps not fully entrapped.  
 
At the conclusion of the experiment, the hydrogels were defrosted and digested in Proteinase K 
according to the protocol outlined in section 2.9.2. The digested gels as well as the wash and elution 
buffers were analysed via gel electrophoresis (section 2.3.1). A standard curve was constructed using 
naked siRNA stocks and run alongside the buffer and digest samples. 
 
2.10 3D Cellular invasion / migration 
 
Cells were entrapped within hydrogels in order to assess cellular invasion and transfection of cells by 
the entrapped nanoparticles. Combination of PEG/PEG and PEG/collagen gels were assessed (section 
2.8).  
 
2.10.1 3D Cellular Invasion from a PEG Hydrogel into a PEG Hydrogel 
 
Both 8-arm and 4-arm PEG hydrogels were used to assess cellular invasion and migration in a 3D 
environment. Varying percentages were tested. For the 8-arm gel, 2% (m/v) gels were prepared and 
for the 4-arm 3.5% (m/v). Flat-bottomed, non-tissue culture treated 96-well plates were siliconized 
prior to starting these experiments and were re-sterilised via gassing.  
 
Gels of 3 µl and 50 µl, containing RGD, were prepared. For the 3 µl gels, cells were suspended in PEG 
gel solution at 40 000 cells/3 µl). Cells were mixed before being individually pipetted into separate 
wells in a 96-well plate and allowed to set. While the gels containing cells were allowed to set, the 50 
µl PEG gels were prepared. The 50 µl gels were then added directly over the 3 µl gels and also allowed 
to set before adding 200 µl of 10% FBS MCDB-131 media. Epidermal Growth factors (100 ng / ml) were 
added to some wells every alternate day. 
 
2.10.2 3D Cellular Invasion – From Dermal Equivalents into PEG Hydrogels 
 
Prior to performing these experiments, 24-well plates were prepared by scoring them with a specially 
made in-house punch and then siliconizing and re-sterilising by gassing (Figure A3.1 of the Appendix).     
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Dermal equivalents were prepared according to the protocol in section 2.8.2.1. After 24-72 hours the 
dermal equivalents were removed from the incubator and carefully placed into PEG hydrogels using 
forceps. The gels were allowed to set for 25-45 minutes in the 37°C, 5% CO2 incubator. Once set, 1 ml 
10% FBS DMEM media was added to each well. 
 
PEG hydrogels of 3.5% (m/v) were made using a 4-arm or 8-arm PEG as described above in section 
2.8.1. Gels were prepared with and without nanoparticles added and the nanoparticles were formed 
using either AllStars Negative Control siRNA Alexa Fluor® 488 or 555, Negative Control siRNA or AllStar 
Hs Cell Death Control siRNA at a concentration of 2 µM siRNA. Once encapsulated the final 
concentration of siRNA inside the gel was 0.75 µM.  
 
The following aspects of cell migration were assessed; ability of cells to invade from a collagen gel into 
a PEG hydrogel and the overall distance migrated, the ability of cells to migrate into gels containing 
nanoparticles was assessed for siRNA internalisation, and efficacy of entrapped nanoparticles once 
they have been internalised by invading cells. Methods for assessment are outlined below. 
 
2.10.2.1 3D Cellular Invasion – measuring cellular migration 
 
The same randomly selected segment of each well containing gel was imaged using a Nikon Eclipse Ti-
S light microscope over a number of days to monitor cell migration. The same area was imaged at each 
time point. The images were analysed using Motic Image Plus 2.0 software to measure the distance 
which the invading cells moved. The distance from the furthest 6 cells to the edge of the dermal 
equivalent was measured and averaged. Accumulated distance was calculated and plotted against 
time. 
 
2.10.2.2 3D Cellular Invasion – Internalisation 
 
When using fluorescently tagged nanoparticles, gels were imaged using a Zeiss LSM510 Confocal 
microscope with ZEN 2009 software. Tile scan Z-stacked images were taken. ZEN 2012 (blue edition) 
was used to compile tile-scan Z-stacked images into compressed images. It was also used to assess 
internalisation of the fluorescently tagged siRNA. The Ortho (orthogonal projection) tool was used to 
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2.10.2.3 3D Cellular Invasion – Efficacy 
 
Efficacy was determined using cell death siRNA nanoparticles. Wells were only imaged on the final day 
of the experiment, when cells were stained using LIVE/DEAD™ cell viability assay (section 2.10.2.3.1). 
Z-stacks were taken using a Zeiss Axiovert 200M Fluorescence microscope with a Zeiss AcioCam HRm 
monochrome camera AxioVision 4.8 software. The area imaged was selected using the green channel 
in order to avoid biased selection. Controls for this experiment were entrapped Negative Control 
siRNA nanoparticles and a non-treated group where no nanoparticles were added. 
 
2.10.2.3.1 LIVE/DEAD® cell viability assay 
 
The LIVE/DEAD® cell viability assay is a commercially available assay used to determine the number of 
living or viable cells present. The assay works based on plasma membrane integrity and esterase 
activity. It is a two-dye system that allows the user to visually distinguish between living and dead 
cells. Ethidium homodimer-1 (EthD-1) is a red fluorescent dye that indicates the loss of plasma 
membrane integrity. Calcein-AM is a green-fluorescent dye which is able to cross the plasma 
membrane and indicates the presence of intercellular esterase activity. Thus dead cells are red and 
live cells are green. The assay was adapted from manufacturers’ guidelines for 2D to 3D and is outlined 
below. 
 
To 10 ml of sterile PBS pH 7.4, 20 µl 2 mM EthD-1 (4 µM) was added and the solution vortexed before 
adding 5 µl of the 4 mM Calcein (2 µM). Media was removed from the wells and washed 1X with 1 ml 
sterile PBS. The PBS was then removed and replaced with 700 µl of the EthD-1 Calcein solution. The 
samples were then incubated for a minimum of 20 minutes and a maximum of 40 before imaging. 
Wells were stained in duplicates and just prior to imaging one pair of wells, the next pair was prepared 
by washing with PBS as above and then adding the EthD-1 Calcein mix to the wells for incubation. This 
process was repeated until all of the wells had been imaged. It has previously observed in our 
laboratory that after > 1 hour exposure to cells in a gel, EthD-1 gains access to live cells turning them 
yellow. 
 
Z-stack images were taken of the wells using a fluorescent microscope after incubation. Images were 
taken using 10X objective magnification using Cy3 (red) and 10 Alexa Fluor 488 (green) reflectors. Both 
the exposure time and the size of the z-stack was optimised when the experiment was first conducted 
and all proceeding experiments were imaged with the same specifications. Exposure times were 687 
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ms and 205 ms for the Cy3 and 10 Alexa Fluor 488 channels respectively. The entire stacks comprised 
of 25 slices each 758 µm thick.  
 
After imaging, individual images from Z-stacks were analysed manually using Zen Blue software. When 
analysing wells containing cell death siRNA, as previously mentioned, green cells represented those 
cells which are living and red cells represented dead cells. Zen Blue was used to mark each of the red 
cells and end up with a final count of number of dead cells. Results were normalised to wells containing 
non-treated cells. 
 
2.10 Statistical analyses 
 
STAT Plus was used for statistical analysis. Results are expressed as the mean and error bars are 
standard error of the mean (SEM) unless otherwise stated. Comparisons between more than two 
groups were analysed by analysis of variance (ANOVA) followed by the Tukey-Kramer post hoc testing. 
A probability value of less than 0.05 was considered to be significant. Though data is represented 
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3. Results & Discussion 
 
The aim of this project was to determine the feasibility of using enzymatically degradable PEG 
hydrogels to localise delivery of complexed siRNA. Assays establishing the use of PEI to complex siRNA 
into nanoparticles and the techniques required for this were initially developed. Towards entrapment 
and delivery, various techniques were developed and assessed. The development of a 3 dimensional 
(3D) cellular invasion assay for the analysis and potential optimisation of siRNA delivery in vitro prior 
to in vivo work being conducted formed part of this assessment. Additionally, the potential for added 
protection via hydrogel encapsulation from degradation by ribonucleases was assayed. The results 
achieved, and the various techniques used are outlined below. 
 
3.1 Establishment of PEI/siRNA nanoparticles 
 
PEI/siRNA nanoparticles are formed based on a ratio of amine nitrogen’s found on PEI to phosphates 
on the siRNA backbone known as an N:P ratio. The optimal N:P ratio with regards to the complexation, 
stability, cytotoxicity and internalisation was established. 
 
3.1.1 Nanoparticle Formation 
 
Nanoparticle formation was assessed via a gel retardation assay. Agarose gel electrophoresis was used 
to assess complex formation as it allows for the separation of non-complexed siRNA from complexed 
siRNA (Figure 2). There have been two proposed explanations given for the inability of polycationic 
complexed siRNA to migrate into an agarose gel. Firstly, elevated steric hindrance due to the increased 
size and/or changed structure of the nanoparticle complexes. Alternatively, when complexed the 
negative charge of the siRNA is negated by the positively charged PEI and as such the nanoparticle 
complex does not run towards the anode94. Of course these two mechanisms can both play a role.  
 
Qualitatively, partial complexation was seen already from the lowest N:P ratio of 0.625:1 with 
complete complexation occurring at 5:1 (Figure 2a). Densitometric analysis confirmed this observation 
with N:P ratios of 0.625, 1.25 and 2.5:1 complexing  27, 58 and 96.5% of the siRNA respectively (Figure 
2b). At 5:1 and higher 100% of siRNA was complexed. Though it might be postulated that all ratios 
below 5:1 needed no further characterisation as incomplete complexation was achieved, only the 
0.625:1 ratio was excluded for further analyses in this section due to its inability to fully complex 
siRNA. Although all three of the lower ratios did not fully complex the siRNA and may thus not be 
expected to perform optimally for RNase protection and transfection efficacy, lower ratios have been 
assayed by others and found to be effective263. 




Figure 2: Gel Retardation Assay: (a) PEI/siRNA complexes formed at a range of ratios resolved on a 4% agarose gel. (b) 
Densitometric quantification of gel retardation assay. Data was normalised to non-complexed siRNA. n = 2 (biological 
repeats).  
 
3.1.2. Complex Stability: Protection of siRNA from RNase Degradation 
 
siRNA is subject to degradation by RNases found in serum and their inhibition has been previously 
shown to improve siRNA half-life257,264. RNA is more susceptible to degradation by ribonucleases than 
other nucleic acids. This is because DNA contains the sugar deoxyribose whereas RNA has the sugar 
ribose in its backbone. The ribose has a hydroxyl group in the 2’ position of the pentose ring which 
renders the RNA more vulnerable to hydrolysis by serum nucleases265,266. Therefore an important 
aspect of complexation by polycations is their ability to potentially sequestrate the siRNA from 
degradation by serum RNases. 
 
The ability of the various ratios of PEI:siRNA to protect the siRNA from RNases was thus assessed by 
incubating the nanoparticles in 50% serum55,257,259,264 at 37°C over a period of 7 days. After incubation 
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the nanoparticles were disrupted by exposure to SDS and the relative amounts of siRNA assayed using 
agarose gel electrophoresis (Figure 3a).  
 
After 1 hour incubation none of the uncomplexed siRNA (0:1) was still present in the samples. An 
unidentified contaminant that originates from serum can be observed running above the siRNA band 
but is well separated. The 1.25 and 2.5:1 ratios achieved the lowest levels of protection with 60 ± 5% 
and 40 ± 16% of siRNA being degraded within first 6 hours respectively (Figure 3b). The 1.25:1 ratio 
was 95 ± 3% degraded within the first 24 hours and by 72 hours had completely degraded. While the 
2.5:1 ratio fared slightly better, after 72 hours 99% of siRNA had been degraded. The results achieved 
here were not unexpected as these ratios did not achieve complete complexation (section 3.1.1). The 
5:1 ratio was the lowest ratio which achieved full complexation. After 72 hours, 18 ± 5% still remained 
but by 168 hours only a minimal 2 ± 1% remained. After 7 days, the 5:1 ratio had a lower level 
remaining than the adjacent ratio of 10:1.  The 10, 20 and 40:1 ratios achieved the highest levels of 
protection after 7 days (Table 4) with increase protection proportional to PEI ratio. 
 
Table 4: Percentage siRNA remaining per ratio after 7 days exposure to RNases present in FBS (± SEM) n = 3 (biological 
repeats) 
 0:1 1.25:1 2.5:1 5:1 10:1 20:1 40:1 
% siRNA 0 ± 0 0 ± 0 0 ± 0 2 ± 1 48 ± 9 53 ± 13 66 ± 12 
 
As previously mentioned (section 1.2.1.2), high and repeated dosages of naked siRNAs have been used 
to deliver siRNA in vivo. This is partly due to rapid degradation by the ribonucleases present. It is 
therefore apparent that maintenance of dosage by increased protection is both important and 
desirable. The potential dosage reduction might reduce side effects.  Previous studies have also 
demonstrated the vulnerability of uncomplexed and unmodified siRNA in serum and showed that 
even in a 1% solution of Foetal Calf Serum, the siRNA is fully degraded within 15-30 minutes143,165. To 
our knowledge RNase protection of polycationic complexed siRNA has not been examined beyond 24 
hours267. A reduction in degradation observed here for up to 7 days is especially important in the 
context of scaffold based localised and controlled delivery of siRNA where longer persistence times 
would be desirable. Thus, the protection garnered to the siRNA by the higher ratios, where a 
substantial amount of siRNA is still available at 7 days, is promising. It has been proposed that 
encapsulation of nanoparticles in a scaffold may allow for further additional protection226. This aspect 
is examined in greater detail later. 





Figure 3: Ability of PEI to protect siRNA from degradation. RNase degradation of siRNA was measured by exposing complexes to RNases present in FBS. (a) Samples were resolved of a 4% agarose gel. Qualitatively, 
the optimal ratio for protection from degradation appears to be from 10:1 and higher as siRNA is still present at 7 days.  (b) Band quantification of the siRNA present from each of the respective ratios over time. At 
7 days the 10, 20 and 40:1 ratios were able to protect the siRNA from degradation at a significantly higher level compared to the lower ratios of 0, 1.25, 2.5 and 5:1 (*p < 0.05).  n = 3 (biological repeats). Arrow 
indicates serum contaminant.  
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3.1.3 Cytotoxicity of PEI/siRNA ratios 
 
As previously stated, PEI is a commonly used transfection agent however, it has also previously been 
reported as being cytotoxic150. Moghimi et al268., conducted a study to elucidate the cytotoxic effects 
of PEI and found that its use can cause membrane damage and induce apoptosis. A possible cause of 
the reported cytotoxicity is the PEI being in excess and it has been shown that partial purification of 
PEI nanoparticle complexes can result in a reduction in cytotoxicity269. However, with this reduction, 
a reduction in transfection efficacy was also reported269. As such in determining the optimal ratio of 
PEI/siRNA it is important to first determine the relative cytotoxicity of the PEI.  
 
Negative control siRNA, was complexed with PEI to allow for the detection of cytotoxicity. This form 
of siRNA (a scrambled sequence) is reported by the manufacturers to have no known homology with 
any identified mammalian gene. Samples were analysed using the CellTiter-Glo® Luminescent Cell 
Viability Assay that determines the number of metabolically active cells present. The levels of ATP 
which are measured by the assay are generally considered to be directly proportional to the number 
of metabolically active cells261. 
 
 
Figure 4: Relative cytotoxicity of a range of PEI/siRNA nanoparticles using Negative Control siRNA. Cells were treated for 
4 hours and incubated for a further 48 hours with media. Treated wells were normalised to non-treated wells and the 
percentage cells remaining determined 48 hours post transfection. (*p < 0.05 versus to the non-treated cells) n = 3 (3 technical 
repeats per biological repeat).  
 
Significant levels of cell death due to cytotoxicity were seen only at the 40:1 ratio (p < 0.05 versus non-
treated cells) (Figure 4). There was no significant difference in the number of viable cells between 
ratios 0:1 (naked siRNA), 1.25:1, 2.5:1, 5:1, 10:1 and 20:1 compared to the control wells (non-treated 
cells). This result suggests that the 40:1 ratio is not optimal due to cytotoxicity. 
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3.1.4 Efficacy of siRNA transfection 
 
The efficacy of delivered siRNA was determined using AllStars Hs Cell Death Control siRNA. 
Determining efficacy is essential as although there might be complexation (as determined by gel 
retardation assay, section 3.1.1), nanoparticles may be ineffective at delivering the siRNA across the 
cell membrane and releasing them into the cytoplasm.  
 
AllStars Hs Cell Death Control siRNA is a commercially available siRNA that targets a range of 
ubiquitously expressed genes which are essential to cell functioning. This form of siRNA was selected 
as the cell death due to successful transfection is readily quantifiable with the CellTiter-Glo® assay 
(Figure 5). 
 
Figure 5: Measuring the efficacy of internalised siRNA and comparing efficacy with cytotoxicity. AllStars Hs Cell Death siRNA 
was complexed at a range of N:P ratios in  order to determine efficacy. Cell death was normalised to wells containing cells 
which were non-treated with nanoparticles. Results displayed allow for the comparison between cytotoxicity and efficacy to 
be easily made and to more clearly demonstrate the effectiveness of the delivery modality. (*p < 0.05 versus the non-treated 
cells) (~ p < 0.05 versus 20:1 ratio used to assess cytotoxicity) n = 3 (3 technical repeats per biological repeat).  
 
A trend was observed with an increase in cell death as the N:P ratio increases.  As would be expected 
from the literature, no evidence of cell death was observed for the naked siRNA (0:1). This was also 
observed for the 1.25 and 2.5:1 ratios. The 5:1 ratio achieved on average approximately 20% cell death 
and the 10:1 27%. However, significantly higher levels of cell death were only observed for the 20:1 
ratio and 40:1 ratio with a 40 and 50% decrease in cell viability (p < 0.05 versus the non-treated cells). 
Results were collated to allow for the easy comparison of efficacy and cytotoxicity. There was 
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significant difference in the levels of cell death seen in those wells treated with the 20:1 cell death 
siRNA ratio relative to the 20:1 negative control siRNA ratio (p < 0.05 versus 20:1 negative control 
siRNA).  However there was no significant difference seen when comparing the cell death siRNA and 
the negative control siRNA at the 40:1 ratio. 
 
3.1.5 Selection of optimal ratio  
 
The data analyses indicates that the 20:1 ratio is optimal. The higher ratios of 10:1, 20:1 and 40:1 were 
generally superior to the lower ratios. A significantly higher level of RNA was preserved from RNase 
degradation for the above ratios. The 40:1 ratio did have a relatively higher level remaining at 2 days 
compared to the 10:1 and 20:1 ratios. However, the 40:1 ratio showed significant levels of cytotoxicity. 
Effective gene knockdown is perhaps the most important consideration when determining an optimal 
PEI/siRNA formulation. Only the 20:1 and 40:1 ratios showed significant and relatively substantial 
levels of gene knockdown. The 20:1 was considered optimal as it is clear that a portion of the 
knockdown efficacy of the 40:1 ratio could be attributed to its cytotoxic effects. Additionally, the small 
increase in knockdown achieved by the 40:1 was not significantly greater than that by the 20:1. It 
should be noted that although the cell death siRNA allows for easy quantification, the results can be 
complicated by cytotoxicity. However, the outcome here was clear and additional experiments 
utilizing other assays such as anti-GFP siRNA were not considered necessary. Levels of cell death 
recorded at a ratio of 40:1 for the cell death siRNA treated wells versus the negative control treated 
wells were not significant, whereas for the 20:1 ratio these levels were significant. This would indicate 
that a large proportion of the cell death seen at a ratio of 40:1 was due to PEI toxicity rather than due 
to the action of the siRNA as seen for the 20:1 ratio.  
 
It has been suggested that having PEI in excess, in other words free PEI, contributes to its efficacy as 
a delivery agent169–171,269. However, an overabundance of PEI leads to a higher degree of toxicity171. 
This could explain the differences seen in the ratios which achieved full complexation (Figure 2). The 
5:1 and 10:1 ratios may have insufficient excess PEI whilst the 40:1 ratio too great an excess resulting 
in cytotoxicity. The 20:1 may have had an optimal excess. It is also possible that insufficient charge 
shielding occurred with the lower ratios resulting in inadequate cell ingress. 
 
This work supports and corroborates the study of Kwok et al270. They too achieved full complexation 
from a ratio of 5:1 as determined by gel retardation assay (Figure 2). Unlike here where Cell Death 
siRNA was used to assay efficacy in HT1080 cells, Kwok and colleagues270 used anti-luciferase siRNA in 
Neuro-2A luciferase expressing cells. Anti-EGFP siRNA was used as a negative control. The second 
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largest knockdown in luciferase expression (60%) was reported for cells treated with the 20:1 ratio. 
This is similar to the efficacy results achieved here as the 20:1 ratio also achieved the second largest 
levels of knockdown determined here by cell viability (Figure 5). While a larger decrease in luciferase 
was seen after treatment with the 40:1 ratio, this was attributed to cytotoxicity as a similar decrease 
in luciferase expression was also reported for cells treated with anti-EGFP siRNA at this ratio. 
Cytotoxicity assay confirmed this and cell death of approximately 20 and 40% was seen for both the 
20:1 and 40:1 ratios. No noticeable cell death due to cytotoxicity was seen for the 20:1 ratio in this 
project. This could be due to HT1080 cells being a more robust cell-line compared to the Neuro-2A 
cells used in the Kwok study. 
 
3.1.5.1 Nanoparticle characterisation: Size and zeta potential for 20:1 ratio 
 
Subsequent to determining an optimal ratio, the size of PEI/siRNA nanoparticles formed at a ratio of 
20:1 was determined by dynamic light scattering (Appendix A4). The mean size of the complexes was 
74.165 nm with an average polydispersity index (PDI) of 0.1875. PDI is a measure of the particle size 
distribution. A PDI between 0.1-0.3 is considered good as it indicates a high proportion of particles are 
of similar size. The zeta-potential was measured at 56.7 mV ± 6.22 mV. Both of these are within range 
in order to achieve optimal delivery.  
 
Complex size and charge can negatively impact on siRNA internalisation and are therefore important 
considerations. It has previously been suggested that in order to achieve non-specific uptake by 
clatherin coated pits, complexes should be between 50 and 150 nm in size, beyond which 
nanoparticles are unlikely to be passively endocytosed265,271.  As with size, particle charge is important 
in order to promote cellular uptake. Negatively charged siRNA is not likely to be passively taken up by 
the negatively charged cell membrane. By donating an overall positive charge, siRNA internalisation is 
promoted, however, in vivo other complications which lead to nanoparticles aggregation could occur 
and should be considered. Physiological salt conditions could lead to a reduction in repulsive forces 
between nanoparticles resulting in aggregation and nanoparticle complexes too large to be 
internalised272. Another concern in vivo would be the interactions between complexes and negatively 





Results and Discussion   
60 
 
3.2 Towards localised delivery 
 
Enzymatically degradable PEG hydrogels have been shown to have a wide range of utility including 
growth factor delivery. More specifically with regard to siRNA delivery, these types of gels have been 
used as a therapeutic vehicle delivering microspheres containing growth factors255. They have been 
used to promote angiogenesis, bone growth, wound healing and also provide mechanical support to 
an infarcted heart. An advantage of the form of PEG hydrogel proposed here, for the localised delivery 
of siRNA, is that it is both injectable and self-polymerising. Their use negates the need for complicated 
surgical procedures that would otherwise be required to implant pre-fabricated hydrogels. This form 
of hydrogel also does not require an external light source for gelation to occur. Non-polymerised 
hydrogels can be delivered to otherwise hard to access areas via catheter where self-polymerisation 
can take place once delivered. As detailed above in sections 1.4.1 and 1.5, several forms of 
hydrolytically degradable and photocroslinkable forms of PEG have been explored as a means of siRNA 
delivery211,229. This study aimed to extend the repertoire of PEGs investigated for the delivery of RNAi 
particles to include Michael addition reaction based spontaneously polymerising and enzymatically 
degradable forms201.  
 
The fundamental aim of this project was to assess the feasibility of using enzymatically degradable 
PEG hydrogels to deliver siRNA complexed with PEI. After establishing an optimal ratio with which to 
formulate PEI/siRNA nanoparticle complexes, the formulation was then used to assess the PEG 
hydrogels utility as an RNAi delivery depot. 
 
3.2.1 Optimal Concentration for nanoparticles 
 
Various facets of nanoparticle entrapment and release were considered and examined. These included 
determining the optimal concentration of siRNA for nanoparticle formation. Due to the nature of PEG 
hydrogels, the volume of nanoparticles that can be added is somewhat limited. At a maximum possible 
concentration of the PEG monomer and the peptide crosslinker, the volume available in a 50 µl 
hydrogel for example is 26.8 µl for the nanoparticle solution. In order to maximise the amount of 
siRNA that could be loaded into a hydrogel at a 20:1 N:P ratio a range of siRNA concentrations were 
assayed. A maximal dosage of siRNA was considered necessary at it should maximise any release of 
nanoparticles from a gel and increase the probability of an invading cells encountering nanoparticles. 
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The relative cytotoxicity of nanoparticles formed at a range of concentrations of siRNA was initially 
assessed using negative control siRNA (section 3.1.3). None of the concentrations were found to be 
significantly cytotoxic (Figure 6a).  
 
The optimal concentration with which to form nanoparticles for transfection (which would then be 
used for entrapment) was determined using AllStars Hs Cell Death Control siRNA as was previously 
done for earlier efficacy experiments (section 3.1.4). Nanoparticle complexes were formed at a range 
of concentrations of siRNA from 0.75 - 7.5 µM. While various concentrations of siRNA were used to 
treat cells, the absolute amount of siRNA for transfection was maintained at 0.075 µM siRNA per 
treated well. As the concentration at which the nanoparticles were formed increased there was a 
trend towards a decrease in efficacy (Figure 6b). Nanoparticles formed at an siRNA concentration of 
0.75 µM achieved the highest levels of cell death (61 ± 8% cell death). Higher concentrations 
maintained this level of transfection until a concentration of 7.75 µM siRNA was used. Here there was 
a significant decrease in the efficacy relative to 0.75 µM siRNA nanoparticles (p < 0.05). Indeed no 
significant difference was observed for this concentration relative to untreated cells. 
 
It has previously been shown that due to charge interactions over time, PEI nanoparticles can form 
aggregates273. These aggregates are too large to gain cell entry and are therefore ineffective at nucleic 
acid delivery. Both PEI and siRNA are charged molecules which enables their interaction and 
spontaneous complexation into nanoparticles. With this there is a reduction in the charge difference 
and therefore a reduction in repulsion which over time can lead to particle aggregation. Under 
physiological conditions such a situation is worsened due to the repulsion forces being screened265,272. 
Sharma et al273., conducted a mechanistic study of PEI/DNA complex aggregation. They reported on 
various conditions which would affect aggregation including that at higher concentrations complexes 
are more likely to aggregate over time. The lack of transfection efficiency at higher concentrations 
observed here most likely reflects the influence of this concentration induced aggregation. 
 




Figure 6: Effect on cytotoxicity and efficacy of different concentrations of PEI/siRNA nanoparticle complexes. HT1080 cells 
were treated with various concentrations of siRNA while maintaining the same N:P ratio of 20:1. (a) Cytotoxicity of various 
concentrations of siRNA nanoparticles. (b) Efficacy of siRNA nanoparticles formed at different concentrations (*p < 0.05 versus 
non-treated cells). n = 3 (3 technical repeats per biological repeat). 
 
Potential particle aggregation was further examined by heparin dissociation. Complex stability for the 
range of siRNA concentrations was assessed using anionic heparin (Figure 7). Each of the various 
concentrations of siRNA were exposed to heparin at a range of concentrations (0 – 5 U/ml). Heparin 
can cause the dissociation of nanoparticles by competing with the siRNA binding to PEI144,274. It was 
hypothesised that if the nanoparticles were aggregating, heparin would be unable to fully compete 
and dissociate siRNA from the PEI. 
 




Figure 7: Stability of various concentrations of siRNA nanoparticles in heparin sulfate. Nanoparticles formed at a range of 
siRNA concentrations and exposed to increasing concentrations of anionic heparin sulfate. Nanoparticles formed at a 
concentration of 7.5 and 3 µM were significantly less dissociated compared to nanoparticles formed at higher concentrations. 
The nanoparticles formed at 3 µM were also significantly more dissociated compared to the concentration of 7.5 µM                 
(*p < 0.05). 
 
Nanoparticle complexes formed at higher concentrations (3 and 7.5 µM siRNA) were harder to 
dissociate with heparin than lower concentrations (0.75 – 2 µM). At 5 U/ml heparin nanoparticles 
formed at a concentration of 3 and 7.5 µM siRNA were significantly less dissociated than nanoparticle 
complexes formed at a concentration of 0.75, 1.5 and 2 µM (p < 0.05). There was also a significant 
difference between the nanoparticles formed at an siRNA concentration of 3 µM and 7.5 µM                    
(p < 0.05). 
 
The inability of complexes to dissociate at higher concentrations could be part of why siRNA efficacy 
(Figure 6b) was ineffective at these concentrations. Nanoparticles are required to release the siRNA 
upon entering the cell. The heparin dissociation assay gives an indication of the ability of the 
complexes to release the siRNA once the complexes have entered the cell270. The formation of 
aggregates may have compromised the ability of heparin to compete equally with the siRNA to bind 
PEI resulting in a lack of dissociation. The formation of large nanoparticle aggregates could therefore 
effect efficacy in two aspects. Firstly, larger aggregates are unlikely to be endocytosed due to their 
size and secondly the complexes inability to release siRNA if it was endocytosed would be deleterious 
for effective transfection.  
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A siRNA concentration of 2 µM for formation of nanoparticles was selected for future experiments. 
The 7.5 µM concentration was discarded due to the marked impairment in transfection efficacy and 
the reduced heparin driven dissociation observed for the 3 µM siRNA concentration raised concerns.  
 
It should be noted that the finding of a concentration related decrease in efficacy may be specific to 
branched PEI. Nguyen et al206., formed nanoparticles with linear PEI modified with GMA at 37 µM 
siRNA and did not report any transfection complications. 
 
3.2.2 Entrapment of nanoparticles 
  
Nanoparticles were formulated at an optimal N:P ratio and siRNA concentration of 20:1 and 2 µM 
siRNA prior to being entrapped within an 8-arm PEG hydrogel and imaged. The confocal micrograph 
illustrates nanoparticle entrapment within the hydrogels (Figure 8). The compressed Z-stack allows 
for the visualisation of nanoparticles throughout the stack in 2D (Figure 8a). A 3D rendering also 
illustrates the distribution of the nanoparticle and demonstrates the even distribution of the 
nanoparticles throughout the depth of the hydrogel (Figure 8b). Having an even distribution of 
complexes is important for invading cells to ensure an equal likelihood that all cells invading encounter 
nanoparticle complexes. The entrapped nanoparticles appear to be sterically entrapped however 
further analysis was needed to confirm this. 
 




Figure 8: Nanoparticles (formed with Alexa 555 labelled siRNA) entrapment within an 8-arm PEG hydrogel. Maximum 
intensity projections of nanoparticle suspended within a gel. (a)  Compressed Z-stack of nanoparticles in a PEG hydrogel. (b) 
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3.4 RNase protection within a PEG hydrogel 
 
The potential for PEI/siRNA nanoparticle entrapment within PEG to provide additional protection to 
siRNA was investigated. Any additional protection from degradation from ribonucleases present in the 
serum would be beneficial for controlled release in vivo over a period of time where nanoparticles 
would be exposed to RNases. To our knowledge this has not previously been assessed although it has 
previously been proposed that scaffolds could provide additional protection from RNase 
degradation226. A novel RNase protection assay was developed by building upon experiments 
previously conducted for section 3.1.2. Eight-arm PEG hydrogels with entrapped nanoparticles were 
placed in FBS and hydrogels removed at various time points over 7 days. To analyse entrapped 
complexes after incubation in serum, Proteinase K was used to digest hydrogels. This digestion was 
carried out in the presence of SDS which enhances Proteinase K activity, dissociates the siRNA from 
PEI, and along with the Proteinase K would have also served to denature any ribonuclease that may 
still have been present in the sample. The digests were analysed by agarose gel electrophoresis. 
 
Degradation of siRNA can be seen to occur in both nanoparticles and nanoparticles encapsulated in 
PEG hydrogel when incubated in serum (Figure 9a and b). However, upon quantification a significant 
decrease in degradation was observed for encapsulated nanoparticles relative to nanoparticles alone 
in serum at 24 hours (p < 0.05) (Figure 9c). Though no longer significant, the protection appeared to 
be maintained for 5 days. By 7 days the additional protection was lost. 
 
Though a relatively minor protection (0 ± 3% vs 17 ± 3% degraded for encapsulated and nanoparticle 
alone respectively at 24 hours), this finding does indicate the potential of hydrogel encapsulation to 
deliver additional protection against RNase attack. It might be that these types of hydrogels with mesh 
size in the 10-20 nm range202 are more protective than hydrogels with less potential for steric 
hindrance such as collagen. This aspect requires further examination. 




Figure 9: Ability of PEG hydrogel to protect encapsulated and complexed siRNA from degradation by RNases. Nanoparticles 
entrapped within a hydrogel and free nanoparticles, were incubated in FBS concurrently or DEPC treated H2O. (a) 20:1 
nanoparticle complexes alone resolved on a 4% agarose gel. (b) 20:1 nanoparticles entrapped within in an 8-arm PEG hydrogel 
resolved on a 4% agarose gel. (c) Densitometric quantification 20:1 nanoparticles alone in FBS, 20:1 nanoparticles entrapped 
within PEG hydrogels placed in FBS and 20:1 nanoparticles entrapped within PEG hydrogels placed in DEPC treated H2O. 
Extent of digestion was normalised to T = 0 samples. There was a significant difference in protection at 24 hours between 
entrapped nanoparticles (in FBS) and non-entrapped nanoparticles (in FBS) (*p < 0.05). n=5 (2 technical repeats per biological 
repeat).
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3.5 Hydrogel Release of Nanoparticles 
 
If scaffold based delivery is to be successful, an important aspect of its success is maintaining the 
bioactivity of the entrapped siRNA. Another aspect to consider is the release profile. A sustained 
release rather than a sudden burst release of siRNA would be desirable, in order to have a prolonged 
silencing effect in surrounding tissue275.  
 
It is hypothesized that due to a mesh size in the 10-20 nm range202, these hydrogels are able to 
sterically entrap nanoparticles and therefore may be unable to elute siRNA nanoparticles unaided by 
enzymatic degradation. It was therefore necessary to conduct a release experiment to confirm this 
hypothesis. 
 
Initially, 8-arm PEG hydrogels were used to entrap either naked siRNA or siRNA complexed with PEI at 
a ratio of 20:1. The gels were placed in elution buffer, and samples from the various time points stored 
at -65°C until the completion of the experiment. After the experiment had run its course, nanoparticles 
were dissociated with SDS. Non-complexed siRNA which was entrapped within the 8-arm hydrogels 
appeared to have eluted extensively in the first 24 hours (Figure 10a) and densitometric analysis 
(Figure 10b) confirmed that essentially 100% had eluted in that period. No siRNA was visible in elution 
aliquots from hydrogels containing PEI/siRNA nanoparticles over the duration of the experiment and 
none could be detected by densitometry.  
 
A 4-arm PEG hydrogel was then also assessed for release in the same way as the 8-arm hydrogel. The 
4-arm hydrogel used here has larger mesh size than the 8-arm version (20 vs 10 nm for 4 and 8-arm 
respectively202  (personal communication from the Polymer Unit)) and would therefore be more likely 
to allow elution of the nanoparticles. Once again however, the PEI/siRNA nanoparticles were 
entrapped for the duration of the experiment within the hydrogel while the uncomplexed siRNA 
eluted within 24 hours (Figure 10a and b).  
 
It is however possible that a negligible amount of nanoparticles had in fact eluted but this would have 
been below the detection limit of the assay (< 2.5% siRNA loaded). These results confirm that the 
nanoparticle complexes were firmly entrapped within the hydrogels and that without complex 
formation the siRNA alone will elute out of the gel. It is probable that this is due to increased steric 
hindrance as PEG gels have minimal ionic charge and the nanoparticle size of 57 nm does exceed the 
mesh size. 
 




Figure 10: siRNA and nanoparticle release from 4- and 8-arm PEG hydrogels. Hydrogels were incubated in a 25 mM HBS 
elution buffer. At 1, 24, 72, 120 and 168 hours hydrogels were placed in fresh elution buffer. Hydrogels were digested and 
along with elution samples were assessed for the presence siRNA and PEI/siRNA nanoparticles. (a) Elution buffer samples 
resolved on a 4% agarose gel. (b) Densitometric analysis of elution buffer samples. For quantification samples were run with 
a standard curve. 
 
3.5.1 PEI/siRNA nanoparticle release from PEG hydrogels to assess bioactivity  
 
A possible approach to overcome the lack of release observed above (section 3.4) was to digest 
hydrogels using Proteinase K in order to assess the bioactivity of the entrapped nanoparticles. Unlike 
for the release experiment and RNase protection assays however, SDS could not be used as it 
dissociates the PEI/siRNA nanoparticles and is toxic to cells. 
 
Proteinase K works optimally at 37°C and digests the hydrogels over a number of hours. Due to 
concerns regarding the increase in aggregation of PEI nanoparticles seen over time at higher 
temperatures273, a time course study was conducted to determine if a limitation of digestion time 
might be required such that a reduction in efficacy of nanoparticles would not occur. Nanoparticles 
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were formed using Cell Death siRNA (2 µM), and were incubated at room temperature (RT) and at 
37°C before being used for transfection experiments. Freshly prepared complexes were used as 
controls and surviving cell levels were normalised to non-treated cells. A drop in transfection efficacy 
could be observed within 1 hour at RT with a further drop at 2 hours (Figure 11). Incubation at 37°C 
resulted in a drop to levels equivalent to 2 hours at RT within 1 hour and this remained at 2 hours. 
This is in agreement with the previously cited study that found nanoparticles aggregation increased 
over time with an increase in temperature273 and suggests that the drop in transfection seen here is 
due to aggregation. Though this experiment was carried out at the concentration of particles at which 
they were formed, it strongly indicated that digestion of hydrogels in Proteinase K should be carried 
out as rapidly as possible. 
 
 
Figure 11: Transfection of HT1080 cells using complexes incubated for various lengths of time at room temperature and at 
37°C. Cells were normalised to non-treated cells. T = Time in hours. RT = Room temperature. n = 3 (technical repeats). 
 
It was deemed ideal if a concentration of Proteinase K that could digest the PEG hydrogels within 1 - 
2 hours could be determined. Proteinase K is a relatively non-specific serine protease and as such its 
activity affects cell adhesion276. Unfortunately difficulties were encountered when attempting to 
digest the gels in this amount of time. High concentrations of proteinase K (1 mg/ml) were needed in 
order to digest the hydrogels in 2 hours (Figure 12a and b). When HT1080 cells were treated with 
digested gel solutions, complete lifting of all cells was observed within 10 minutes. This was also 
observed in the presence of 20% (v/v) serum and in the presence of Pefabloc® Sc. Pefabloc® Sc is a 
specific, irreversible serine protease inhibitor that is the only one to our knowledge which is reported 
to be a non-cytotoxic inhibitor of proteinase K available. As a last resort gels were digested overnight 
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in 100 µg/ml Proteinase K. Substantial loss of cell adhesion and cell lifting was still observed at this 
lower concentration of Proteinase K. Thus, in our hands it was not possible to digest gels such that an 
adequately rapid release could be achieved without substantial to complete loss of cells. 
 
Figure 12: HT1080 cells treated with digested 1 mg/ml Proteinase K. (a) Untreated HT1080 cells. (b) Cells treated with a digested PEG hydrogel. 
A large proportion of cells treated with Proteinase K lifted within 10 minutes of treatment.  
3.6 3D cell culture 
 
As it was not possible to simply release nanoparticles for efficacy assessment, 3D cell invasion assays 
were explored. A 3D in situ assay which does not rely on release but rather cellular invasion is also a 
closer mimic of the in vivo scenario for these types of enzymatically degradable hydrogels.   
 
3.6.1 Cells cultured in 3D with siRNA nanoparticles 
 
In initial experiments to assess whether cells can take up encapsulated siRNA nanoparticles, hydrogels 
were formed containing both cells and nanoparticles dispersed throughout. This was achieved by 
polymerising gels with both cells and fluorescently labelled siRNA nanoparticles present. As can be 
observed in Figure 13, 100% of cells had been transfected by siRNA. Though this approach has been 
used by others39,205,206,210, the high uptake of siRNA raised concern as cells are directly exposed to 
nanoparticles for a period of 20-30 minutes before complete polymerisation. During this time the 
nanoparticles and cells are in a relatively small volume (high concentration compared to normal 
transfections) and forced into contact. This situation may greatly enhance transfection efficacy and 
reinforces the need for a model that initially isolates the cells from the siRNA containing nanoparticles. 
 




Figure 13: Photomicrographs of HT1080 cells encapsulated in an 8-arm PEG hydrogel with Alexa 488 labelled siRNA used 
to form nanoparticle complexes. Images were taken on a LSM510 Confocal Microscope. (a) Fluorescent image of transfected 
cells. (b) Phase contrast image of the transfected cells seen in image (a). (c) Image overlay of (a) and (b). 
 
3.6.2 3D cellular invasion 
 
It was important that nanoparticles and cells are separated prior to polymerisation, in order to more 
closely mimic an in vivo environment, whereby cells would need to invade an injected enzymatically 
degradable hydrogel after it has polymerised. Two 3D in vitro cell invasion assays were developed in 
order to determine the ability of invading cells to be transfected by the entrapped nanoparticles.  
 
Cells were entrapped within an 8-arm PEG hydrogel which was centred in a siliconized 96-well plate 
and polymerised. Siliconizing the surface of the well creates a hydrophobic coat which aids in creating 
a well-defined hemisphere shape for gels polymerised on such a surface. After the cell containing 
hydrogel had formed a concise hemisphere, a second PEG hydrogel containing nanoparticles was 
polymerised onto the first hydrogel to form concentric hemispheres (Figure 14a). After 
polymerisation, a stimulatory media containing 10% FBS and EGF (100 ng/ml) was added. Minimal 
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invasion was observed to occur into the hydrogel by the cells (Figure 14b and c).  Thus, this approach 
with a PEG gel within a PEG gel, though simple in application, was not suitable. 
 
 
Figure 14: HT1080 cells migrating from a 2% PEG hydrogel into another 2% PEG hydrogel. (a) Schematic of hydrogel setup. 
(b) Migration after 24 hours. (c) Migration after 96 hours. EGF (100 ng/ml) was added to the media on alternate days. 
 
3.6.2.1 Dermal equivalents for implantation into PEG hydrogels 
 
The potential of combining PEG with another hydrogel was assayed. Examination of the literature 
indicated that an approach used by Grinnell et al277., might allow for enhanced invasion. A nested 
collagen matrices protocol277, which involves the preparation and implantation of dermal equivalents 
into a collagen hydrogel, was adapted for use with PEG hydrogels (Figure 15). Dermal equivalents are 
collagen gels which have been condensed over time by  encapsulated cells into a tissue-like 
structure278. They were first developed as a model to study wound healing and fibroblast function in 
vitro279 and later used in skin grafting in vivo280. Cells which have not first been incorporated into 
dermal equivalents, but rather seeded directly onto the surface of a 3D scaffold were shown to 
migrate very slowly into the interior281–283. Cells migrating from the contracted collagen matrices have 
been found to have a much more invasive phenotype and migrate more rapidly into the surrounding 
matrix277. 




Figure 15: Schematic of dermal equivalent in a PEG hydrogel. Dermal equivalents which had condensed were carefully placed 
into polymerizing PEG hydrogels so that dermal equivalent did not sink to the well floor. 
 
Here, tissue culture-treated 24-well plates which had been scored with a specially made surgical punch 
and siliconized were used to monitor cellular ingrowth. Scoring the well helped localise the hydrogels 
to the centre of the wells. Once formed, dermal equivalents were embedded in a PEG hydrogel as per 
diagram in Figure 15. After 48 hours of incubation, dermal equivalents formed using HT1080 cells were 
seen to be elongated (Figure 16). This “tissue-like” behaviour indicates that HT1080 fibrosarcoma cells 
behave similarly to fibroblasts279. 
 
 
Figure 16: Annotated images of dermal equivalent showing the formation of the tissue-like lattice after incubation. HT1080 
cells were used to form the dermal equivalents. (a) 10X objective magnification of area in dermal equivalent. (b) 20X 
magnification of area in dermal equivalent. The red arrows point to examples of cells which have become elongated during 
3D cell culture. 
 
In initial studies, HT1080 containing dermal equivalents were embedded in 3.5% 8- or 4-arm PEG 
hydrogels (Figure 17a and b). By imaging dermal equivalents which were prepared at the same time 
and placed in either hydrogel it was possible to compare migration. Dermal equivalents placed in a 4-
arm PEG hydrogel were able to migrate substantially further than those placed in 8-arm PEG hydrogels 
over the same period of time and under the same conditions. Cells migrated 455 µm in an 8-arm PEG 
hydrogel while they migrated 1232.5 µm in the 4-arm over 7 days (Figure 17a and b). The cells of 
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dermal equivalents embedded in the 4-arm PEG hydrogel also appeared to be more spread out 
compared to those entrapped within the 8-arm PEG hydrogel. In the 8-arm PEG hydrogel it was harder 




Figure 17: HT1080 cellular invasion using 4-arm versus 8-arm PEG hydrogels. Dermal equivalents were placed in either a 4- or 8-arm hydrogel 
and incubated for 7 days after which time they were imaged. The distance migrated of the furthest cell was measured. Dashed lines represent 
dermal equivalent edge. (a) HT1080 cells invading a 8-arm PEG hydrogel. (b) HT1080 cells invading a 4-arm PEG hydrogel. 
 
3.6.2.2 Quantitation of cellular invasion rate 
 
The 4-arm PEG hydrogel which has previously been used in this laboratory for spheroid assays and 
shown to allow cellular ingrowth202 was further assessed with respect to cellular invasion from dermal 
equivalents. Cell migration was monitored over 7 days and imaged (Figure 18a - d). Migration was 
quantified by measuring the distance between the edge of the dermal equivalent and cells which had 
migrated furthest from the dermal edge. The average distance that the leading cells had migrated was 
1129.5 ± 34 µm away from the dermal equivalent edge after 7 days (Figure 18e). The rate of migration 
was highest during the initial 24 hours in which the cells were monitored (17 µm/hour). This rate then 
slowed to 5 µm/hour between 24 and 168 hours (7 days). This rate of cellular invasion was judged to 
be sufficient to assess cellular internalisation of PEI/siRNA nanoparticles. 
 
 




Figure 18: Cellular invasion from dermal equivalents into 3.5% 4-arm PEG hydrogels imaged over 7 days. Representative 
photomicrographs of invading cells imaged over 7 days. (a) Time = 1 hour (b) Time = 24 hours (c) 96 hours (d) 168 hours (e) 
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3.6.3 Cellular invasion into a PEG hydrogel containing fluorescently tagged siRNA 
nanoparticles 
 
In initial analyses of cellular uptake of encapsulated nanoparticles, GFP expressing HT1080 cells were 
used to form dermal equivalents and embedded within a PEG hydrogel containing Alexa 555 labelled 
scrambled siRNA. It was hypothesised that this would allow for determination of cellular 
internalisation of siRNA. After 3 days, tile-scan combined with Z-stacking images were taken using the 
Zeiss LSM510 confocal microscope. This allowed for a significant proportion of the invading cells to be 
captured. A single layer from the central region of the tiled Z-stack is shown in Figure 19. Nanoparticles 
can be seen throughout with arrows indicating examples of cells that appear to have internalised the 
siRNA. These were examined more closely utilising the orthogonal projection modality. 




Figure 19: Enlarged view of HT1080 cells stably transfected with GFP  invading a 4-arm 3.5% PEG hydrogel containing nanoparticles formed with Alexa555 siRNA (Time = 72 hour). Displayed image is from a 
single layer of a Z-stack. Image is representative of other areas. Arrows are pointing to examples of cells which have internalised the siRNA. 
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In order to confirm that the cells in Figure 19 had been transfected by the entrapped nanoparticles it 
was necessary to view an orthogonal projection (Figure 20). The orthogonal projection displays 
multiple views of an object at right angles to each other. For a Z-stack, this allows the user to view the 
x, y and z co-ordinate of a point simultaneously in 2D. The larger field of view (blue border) of the 
orthogonal projection represents a single layer of a Z-stack as if it was viewed from above. The red 
and green lines which intersect are the y- and x-axis respectively and are also represented by the red 
and green boxes (above and to the right respectively). The boxes are a side-on view along the lines of 
the x- and y-axis (as if one were viewing the entire z-stack from the side) (Figure 20a). An analogy of 
this would be if one had to view the cover of a book or individual pages, the large area would be an 
individual page. If one had to draw a line across the width (x-axis) of the book and then cut it along 
that line and view the book from the side, the green box would represent the area now exposed by 
cutting the book along that line. The blue line running across the green box represents the individual 
Z-stack layer or “page” that is being viewed in the larger box. In a similar manner the red box is the 
area that would be created if one had to draw a line along the length of the book (y-axis) and view the 
book from the side of the freshly cut page edges. Figure 19b is a drawing to aid in visualising the above 
description. The colours of Figure 20b correspond to the border colours seen in Figure 20a.  
 
The nanoparticles in the cell (indicated by white arrows) examined in Figure 20a show that they are 
within the green fluorescence of the GFP expressing cell in all planes strongly suggesting uptake. 
However, this approach is extremely labour intensive limiting its applicability as a screening tool in 
part due to the fluorescence of the nanoparticles in the gel. It was hoped that unquenching in the cell 
would have resulted in a greater increase in fluorescence intensity.     
 
The levels of transfection seen here are not necessarily all that high. This is probably due to the 
environment into which the cells are invading. Due to previously discussed constraints surrounding 
concentration of entrapped nanoparticles, the number of possible nanoparticles which cells can 
encounter is dramatically reduced compared to if there was a higher concentration of nanoparticles 
per hydrogel. This could be a possible reason for the low levels of transfection seen.  In 2D based 
experiments the siRNA nanoparticle blanket the cells seeded in the tissue culture plate whereas for 
3D experiments cells have to physically encounter nanoparticles. 
 





Figure 20: Orthogonal projection of an area of invading cells. (a) Orthogonal projection with enlarged areas. Blue: z-view / z-cut line. Green: x-view / y-cut line. Red: y-view / x-cut line. (b) Illustration to help in 
understanding the orthogonal protection. The different perspectives of the same cell indicating cellular internalisation of fluorescently labelled siRNA (white arrows). The large area which is flanked by a red box on 
the right and a green above is a view of the Z-stack if one was looking from above. The different boxes indicate the same region from different viewing perspectives. The green box corresponds to the green line (x-
axis) and is a side on view. The red box corresponds to the red line and is a side view of the y -axis. The blue line represents the layer in the Z-stack which is being viewed from above in the blue box. The blue line 
within the smaller of the two green and red boxes is the areas highlighted by the small blue box.
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3.6.4 Cell invasion into PEG hydrogel containing AllStars Hs Cell Death siRNA. 
 
In order to assay the bioactivity of the entrapped PEI/siRNA nanoparticles, dermal equivalents were 
placed in 4-arm PEG hydrogels containing nanoparticle complexes which were formed using AllStars 
Hs Cell Death siRNA. A LIVE/DEAD™ Cell Viability Assay was used to assess efficacy. This assay enables 
the differentiation between populations of live and dead cells based on plasma membrane activity 
and esterase activity whereby live cells are stained green and dead cells are stained red. 
 
 
Figure 21: Compressed z-stacks of LIVE/DEAD™ cell staining within PEG. (a) Non-treated cells. (b) Cells treated with negative 
control siRNA. (c) Cells treated with Cell Death siRNA. 
 
Figure 21 displays representative compressed Z-stack images of the quantified results. It was clear 
that the number of dead cells relative to the number of live cells was low. It was not possible to 
accurately count the number of living cells due to the lack of availability of a confocal microscope 
during this period. A Zeiss Axiovert fluorescent microscope was used to take these images. While the 
microscope is capable of acquiring Z-stack images the sections are coarser than what they would have 
been had a confocal been used instead. None-the-less careful attention was paid to selecting a region 
using the green channel (living cells) to capture images in order to avoid bias region selection. When 
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quantifying the number of dead cells per image, each layer of the Z-stack was manually examined. 
Attention was given to not count the same dead cells when moving between the layers. 
     
Dead cells were manually counted and results were normalised to non-treated wells (Figure 22). There 
was an increase in number of dead cells in the cell death treated wells but this was not significantly 
different to the non-treated and negative control siRNA treated wells. There was an indication of a 
possible trend with cell death treated cells having a p = 0.065 versus untreated cells whilst negative 
control siRNA treated cells had a p = 0.7 versus the untreated cells. 
 
 
Figure 22: Percentage Cell Death relative to untreated cells. Cells were normalised to non-treated wells a percentage cell 
death relative to that was calculated. Significant levels of cell death were achieved between untreated cells and those treat 
with cell death siRNA. n = 4 (2 technical repeats per biological repeat). 
 
These results are similar in nature to that observed for siRNA internalisation in the previous section 
(3.6.3) suggesting poor uptake of PEI/siRNA nanoparticles. A number of possible issues may have 
played a role. Due to the limited concentration of siRNA achievable when forming nanoparticles, and 
the limited available volume that can be added to a hydrogel, the likelihood of cells encountering 
nanoparticles may have been very low. This could potentially be overcome via the use of alternative 
delivery vehicles that might allow for higher siRNA concentrations during nanoparticle formation. 
Alternatively modifications of the PEI polymer itself may allow for an increase in siRNA concentration. 
Such modifications would need to maintain or improve efficacy in 2D but more importantly prevent 
nanoparticle aggregation. The apparent very tight encapsulation of nanoparticles achieved could have 
potentially exacerbated the lack of interaction with cells. The lack of release (Figure 10) achieved 
suggest minimal movement by the nanoparticles in the hydrogel which would limit the probability of 
a nanoparticle reaching a cell. In this hydrogel system it has been shown that the activity of cellular 
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proteases is localised to the invading cell minimising the possibility of cleavage of sites remote to the 
invading that would allow for release of nanoparticles.  Here the introduction of hydrolytic cleavage 
sites in addition to enzymatically degradable sites might allow for greater movement of nanoparticles 
within and form the hydrogel. In studies where PEI nanoparticles were encapsulated throughout a 
hydrolytically degradable PEG hydrogels (either 8-arm PEG mono(2-acryloyloxyethyl) succinate or PEG 
acrylate), sustained release was obtained and reasonable levels of transfection were obtained. It 
cannot be entirely excluded that encapsulation of the nanoparticles has not damaged them in some 
fashion though it is not clear how this might occur. The PEI may have been covalently coupled into the 
hydrogel via the vinyl sulfone moiety. Though the latter has a very high specificity for thiols, it may be 
possible that it binds to amines. However, as pegylation of PEI is a common modification this seems 
unlikely to have caused significant issues with transfection. Certainly, when the PEG monomer was 
incubated with the nanoparticles prior to transfection no reduction in efficacy was observed (Figure 
A5.1, Appendix A5). 
 
It was originally hoped that this assay would allow for the simple evaluation of PEI/siRNA nanoparticles 
in an environment which more closely mimics the in vivo structure. Although this assay proved to be 
unsuccessful in assessing the bioactivity of entrapped nanoparticles, an in vitro milieu was created 
that resembles an in vivo scenario. It could be envisaged that with a more potent particle, that cell 
death could be monitored by simple analyses of this model that could include cell loss and reduced 















RNAi has great potential for treatment for numerous pathological conditions. Targeted delivery to 
desired regions of interest in the body has impeded its progress to the clinic. Localised delivery from 
injectable hydrogel based scaffolds are one possible way to optimise delivery. Here, various existing 
assays were established in our laboratory as well as assays developed to assess in vitro the feasibility 
of using cationic PEI polymers and a PEG hydrogel system as a therapeutic siRNA delivery vehicle. 
 
The 20:1 ratio was found to be the optimal ratio of nitrogen in PEI to phosphate in siRNA. This ratio 
achieved full complexation, while maintaining siRNA integrity of at least 50% over 7 days. This ratio 
was non-cytotoxic and efficacious at mRNA knock-down. The size and zeta potential of the 20:1 ratio 
was determined to be 74 nm and 57 mV respectively. Both of which are within the optimal range for 
RNAi delivery.  
 
An siRNA concentration of 2 µM was determined to be the optimal concentration at which to form 
nanoparticles for encapsulation in a hydrogel. At higher concentrations the efficacy of the siRNA was 
found to be decreased which was possibly due to aggregation.  This limits dosages achievable with PEI 
based nanoparticles in PEG hydrogel systems such as the one employed here.  
 
It was found that nanoparticles entrapped within a PEG hydrogel had significantly higher levels of 
protection compared to non-encapsulated siRNA nanoparticles within the initial 24 hours which 
persisted up to 5 days. Though the additional RNA protection was lost after 7 days incubation in serum, 
this indicates that PEG hydrogels may be desirable in this context as localised delivery vehicles.  
 
Both 4-arm and 8-arm PEG hydrogels were assessed for nanoparticle and naked siRNA release. Naked 
siRNA eluted within 24 hours whereas the complexed siRNA remained entrapped for at least 7 days. 
This apparent tight entrapment may not be an optimal parameter of the PEG hydrogel system as 
controlled release to surrounds as well as interaction with invading cells would probably be 
substantially reduced.   
 
When hydrogels were polymerised with nanoparticles and cells together, 100% of cells were observed 
to take up siRNA.  It was postulated that this may have resulted from initial uptake whilst reagents 
were in solution and motivated the desire to design models that more closely mimicked the in vivo 
scenario. Cellular invasion experiments where siRNA was initially sequestrated away from the cell 
containing hydrogels were conducted with either PEG/PEG or PEG/collagen combinations. Cells 
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invading from PEG to PEG were shown to only move minimally into the siRNA hydrogel. Cells invasion 
and migration from collagen (dermal equivalents) into either 8-arm or 4-arm PEG hydrogels was far 
more extensive with 4-arm PEG hydrogel allowing maximal 3D cellular migration. 
 
Internalisation of siRNA into invading cells was assayed with a fluorescently labelled siRNA. Successful 
uptake was confirmed by confocal microscopy but level of uptake appeared low and quantification 
was challenging. Thus, an approach which might allow for both simpler quantification and efficacy to 
be determined was developed. Here siRNA sequences that cause cell death were employed in 
conjunction with an assay that can detect dead cells in 3D. Cell death levels achieved were very limited, 
which complicated aspects of quantification, but cell death levels in the experimental group (though 
non-significant) indicated possible successful transfection.  
 
In conclusion, PEI based siRNA nanoparticles have been established in this laboratory as well as assays 
needed for optimisation of PEI and other nanoparticle formulations. An assay determining the ability 
of a scaffold based delivery system to confer additional protection from RNase degradation was also 
developed. A 3D cell invasion that gets closer to the in vivo scenario was established and could be 
easily adapted for use with other hydrogel siRNA formulations. 
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A1: Reagents and Equipment 
 
Table A1.1: Reagents 
Product Producer / Supplier Product Catalogue Number 
Actin RedTM ReadyProbes® Reagent Life Technologies R37112 lot 174846 
Agarose (SeaKem LE) Lonza, Rockland, ME 
 
50004 (500 g) 
AllStars Negative Control siRNA AF488 20 
nmol 
Qiagen, Hilden, Germany 1027292 
AllStars Negative Control siRNA AF555 20 
nmol 
Qiagen, Hilden, Germany 1027294 
AllStars Hs Death siRNA 20 nmol Qiagen, Hilden, Germany 1027299 
Boric Acid Sigma-Aldrich®, St Louis, MO B0394-1KG 
Cell Titre Glo® Luminescent Cell Viability 
Assay  
Promega®, Madison, WI G7571 (10 × 10 ml) 
Diethyl Pyrocarbonate (DEPC) Sigma-Aldrich®, St Louis, MO D5758-100ML 
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich®, St Louis, MO D2650-5X1ML 
DL-Dithiothreitol Sigma-Aldrich®, St Louis, MO D5545-1KG 
DMEM Sigma-Aldrich®, St Louis, MO D5648-10X1L 
EDTA – disodium salt dehydrate 99% Sigma-Aldrich®, Germany E5134-500G 
EDTA – trisodium salt min. 95% Sigma-Aldrich®, St Louis, MO ED3SS-500G 
Foetal Bovine Serum (FBS) (gamma 
irradiated) - 1 
Gibco® by Life Technologies™, Paisley, 
UK 
10499-044 (500 ml) 
Foetal Bovine Serum (FBS) Superior (heat 
inactivated) - 2 
Biochrom GmbH, Berlin, Germany S0615 (500 ml) 
Gel Red Nucleic Acid Gel Stain (10’000X 
in water) 
Biotium, Hayward, CA 41003 (0.5 ml) 
GoTaq® Flexi Buffer 5X Promega, Madison, WI M791B 
Lipofectamine RNAi Max ThermoFisher Scientific 13778030 (0.3 ml) 
MCDB-131 Medium Sigma-Aldrich, St Louis, MO M8537 
MMP-1 
(GCREGPQGIWGQERCG, MW = 1732.91 
g/mol) 
GenScript USA Inc., Piscataway, NJ U5878BB230-1 (100 mg per vile) 
Negative control siRNA (this siRNA has a 
scrambled sequence and as such its 
presence no effect on cellular activity) 
Bioneer Corp., Daedeok District, South 
Korea 
SN-1015 
Hepes (25g) Sigma-Aldrich®, St Louis, MO H4034-25G 
Heparin NaCl Sigma-Aldrich®, St Louis, MO H3393-50KU 
Hydrochloric acid (HCl), 25% w/v Riedel-deHaën, Germany 30723 (2.5 L) 
20PEG8-OH Nektar Therapeutics AL, Coperration, 
AL 
0J000P08 
20PEG4-OH  Nektar Therapeutics AL, Coperration, 
AL 
0J000P04 
Penicillin Streptomycin (10 000 U 
penicillin and 10 mg streptomycin / ml)  
Sigma-Aldrich®, St Louis, MO P0781 (100X concentration) 
Penicillin Streptomycin (10 000 U/ml / 
10 000 µg/ml) 
Gibco® by Life Technologies 15140-122 (100 ml) 
Polyethylenimine (PEI) Branched 100ml 
25 KDa,. 
Sigma-Aldrich®, St Louis, MO 408727-100ML 
RGD (GCGYGRGDSPG, MW = 
1025.06g/mol) 
GenicBio Synthetic Peptide, Shanghai, 
China 
No catalogue number, 100mg 
Sigmacote Sigma-Aldrich®, St Louis, MO SL2-25ML 
Sodium Bicarbonate (NaHCO3)  Sigma-Aldrich®, St Louis, MO S-5761-1KG 
Sodium Chloride (NaCl) Sigma-Aldrich®, St Louis, MO S-7653-1KG 
Sodium Dodecyl Sulfate – SDS Sigma-Aldrich®, St Louis, MO L3771-100G 




Sodium Hydroxide (NaOH) Sigma-Aldrich®, St Louis, MO S-5881-500G 
Sodium Phosphate Dibasic 
Dodecahydrate (Na2HPO4.12H2O) 500g 
Sigma-Aldrich®, St Louis, MO 71649-500G 
Sodium Phosphate Monobasic 
Monohydrate (NaH2PO4.H2O) 
Sigma-Aldrich®, St Louis, MO S9638-500G 
Triethanolamine (TEOA) 99% Saarchem-Holpro Analytic, 
Krugersdorp, South Africa 
6112040 (2.5 L) 
Trypan Blue Sigma-Aldrich®, St Louis, MO T8154-100ML 
Trizma Base® 500g Sigma-Aldrich®, St Louis, MO T6066-500G 
Trypsin (2.5%) (10X) GI 100ml  Sigma-Aldrich®, St Louis, MO 59427C-100ML 
 
Table A1.2: Consumables & Cells 
Product Producer / Supplier Product Catalogue Number 
24-well cell culture cluster, clear, flat 
bottomed, sterile tissue culture 
treated 
Costar® by Corning Incorporated, NY 3524 
96-well cell culture cluster, clear, flat 
bottomed, sterile 
Costar by Corning Incorporated, NY 3595 
96-well opaque flat bottomed non-
sterile plate 
Nunc® MicroWell, Roskilde, Denmark 
by Sigma,  
Z688665 or P8616 
 
96-well non-tc treated Nunc® MicroWell Roskilde, Denmark 
by Sigma 
260887 
Cell culture flask, surface area 25 
cm2, canted neck, cap (vented) 
Corning Inc. Corning, NY CLS430639 
Centrifuge tube (50 ml) Falcon by BD Biosciences, San Jose, 
CA 
352070 
Centrifuge tube (15 ml) Falcon by BD Biosciences, San Jose, 
CA 
352096 
Cuvette Pack of 100 with stoppers (40 
µl) 
Malvern Instruments LTD., 
Worcestershire, UK 
ZEN0040 
Filter, syringe filter unit (0.2 µm) Abluo™, GVS Lifesciences, Sanford, 
ME 
FJ25ASCCA002DL01 
Filter, low-protein binding (0.22 µm 
PES, 250 ml) for cell culture media 
Millipore® Stericup™  
(polyethersulfone membrane, 
Millipore Express PLUS), Merck KGaA, 
Darmstadt, Germany 
Z660493 – Sigma 
SCGPU02RE – Merck 
Folded Capillary Cells – Pack of 10 Malvern Instruments LTD., 
Worcestershire, UK 
DTS1061, now replaced by DTS1070 
HT1080 cells ATCC, Manassas, VA, USA - 
Micro centrifuge tube (with screw 
cap) for freeze-drying samples 
Corning Incorporated, Nuevo Leon, 
Mexico 
430909 
Micro centrifuge tube (graduated) 
with flat cap (0.6 ml) 
Thermo Scientific QSP, San Diego, CA 502-GRD-Q 
Micro centrifuge tube (graduated) 
with flat cap (1.5 ml) 
Thermo Scientific QSP, San Diego, CA 509-GRD-Q 
Micro centrifuge tube (graduated) 
with flat locking cap (2 ml) 
Thermo Scientific QSP, San Diego, CA L-508GRD-Q 
Parafilm M® 4 in. X 250 ft. roll Bemis NA, Neenah, WI PM 999 
 
  




Table A1.3: Equipment and Software 
Product Producer / Supplier 
AxioVision 4.8 Carl Zeiss Microscopy GmbH, Göttingen, Germany 
Cary Eclips, Fluorescence Spectrophotometer Varian, Palto Alto, CA 
Centrifuge (Megafuge 1.0R) Heraeus Sepatech, Hanau, Germany 
Centrifuge 5415R (for micro centrifuge tubes) Eppendorf, Hamburg, Germany 
Freeze Dryer - Virtis SP Industries, Gardiner, NY 
GeneSys image capture and manipulation software 
with GeneTools software 
Syngene, Cambridge, England 
Glomax 96 Luminometer Promega, Madison,  WI 
Haemocytometer Improved Neubauer, Baxter Scientific 
Mini Sub-Cell® GT Agarose Gel Electrophoresis system Bio-Rad Laborities (PTY) LTD, Johannesburg, South 
Africa 
MCO-175M, O2/CO2 Incubator Osaka Sanyo Electric Co., Japan 
Incubator (37 °C) for tissue culture HERA cell by Heraeus, Hanau, Germany 
MCO-175M, O2/CO2 Incubator, Osaka Sanyo Electric 
Co., Japan 
Laminar Flow Hood (Microbiological Safety Cabinet 
Class II, model 4B2) 
Labaire Manufacturing Company, (Pty), Ltd, Mt 
Edgcombe, South Africa 
Nikon Fluorescent Microscope (Nikon Eclipse90i DS-
Ri1) 
Nikon, Tokyo, Japan 
Nikon Light microscope (Nikon Eclipse Ti-S) Nikon, Tokyo Japan 
pH meter (3510 pH meter) Jenway by Bibby Scientific, Staffs, UK 
Pipettes Gilson, Inc. Middleton, WI 
Power Pack Bio-Rad Laboratories (PTY) LTD, Johannesburg, South 
Africa 
Manual Gel Documentation (InGenius3) Syngene, Cambridge, England 
Mini Sub-Cell® GT Agarose Gel Electrophoresis system Bio-Rad Laboratories (PTY) LTD, Johannesburg, South 
Africa 
Motic Image Plus 2.0 Motic, Hongkong 
NIS-Elements BR 2.30 Nikon instruments Inc, Melville, NY 
Shaking incubator IncoShake by Labotech, Cape Town, South Africa 
Water Bath (Grant Y14 water bath) Grant Instruments, Cambridge, England 
Zeiss Axiovert 200M Inverted Fluorescent Microscope Carl Zeiss Microscopy GmbH, Göttingen, Germany 
Zeiss 510 LSM with MaiTai two photon laser Carl Zeiss Microscopy GmbH, Göttingen, Germany 
Zetasizer Nano-Zs (ZEN3600) Malvern Instruments LTD., Worcestershire, UK 
37°C incubator for tissue culture MCO-175M, O2/CO2 Incubator, Osaka Sanyo Electric 
Co., Japan 
Heraeus, Hanau, Germany 














A2: Recipes and instructions for buffers and other reagents 
 
Table A2.1: Components and recipes of various commonly used buffers and reagents. 
Solution Components 
Agarose gel – 4% (m/v) 4 g Agarose / 100 ml TBE 
Add ± 10 ml Barnstead Nanopure H2O extra 
Microwave until agarose dissolved 
Calcium chloride (CaCl2)  55.5 g CaCl2 / 50 ml Nanopure H2O (100 mM) 
DMEM, pH 7.4 13.4 g powdered DMEM medium, 3.7 g NaHCO3 per 1 L Barnstead Nanopure 
H2O 
DEPC treated Barnstead Nanopure 
Water 
0.05% (v/v) solution 
Autoclave  
EDTA (ethylenediamine tetraacitic 
acid), pH 8.0 
37.22 g Na2EDTA.2 H2O / 200 ml Barnstead Nanopure H2O (0.5M) 
 
Isotonic Phosphate Buffered Saline 
(PBS) – Calcium and Magnesium free  
2.9 g/L Na2HPO4.12H2O (8 mM), 0.2 g/L KH2PO4 (1.4 mM), 0.2 g/L KCl (2.7 mM), 
8 g/L NaCl (137 mM) 
Sterilise by autoclaving or by using a 0.22 µm cutoff low protein binding bottle 
top filter 
Iso-Osmotic PBS Sol A: 20.7 g/L  NaH2PO4.H2O  (0.15M)  
Sol B: 53.7 g/L Na2HPO4.12H2O  
NaCl: 9 g/L NaCl (0.15M) 
Combine 65 ml Sol A with 435 ml Sol 
B and 500 ml NaCl. 
pH using Sol A or B only. 
pH to 7.5  
Sterilise by autoclaving or by using a 0.22 µm cutoff low protein binding bottle 
top filter 
Hepes Buffered Saline (HBS) pH 7.4-
7.5 
0.595 g Hepes (25 mM), 0.82 g NaCl (140 mM) / 100 ml Barnstead Nanopure 
H2O 
Loading dye 3 µl Gel Red was added to 1 ml 5X Green GoTaq® Flexi Buffer 
MCDB-131 Medium  pH 7.4 11.6 g MCDB-131 powdered medium, 1.18 g NaHCO3 / 1 L 
Sterilise using a 0.22 µm cutoff low protein binding bottle top filter - stored at 
4˚C 
Penicillin / Streptomycin  Arrived pre-prepared, Stored 1 ml aliquots at -20°C 
Proteinase K – 10 mg/ml stock 25 mg Proteinase K allowed to defrost at room temperature 
Dissolve in 2.5 ml 10 mM Tris-Cl pH 7.3 
Store in 100.2 µl aliquots at -65°C. Stored in non-activated form  
Sodium Hydroxide (NaOH) 10 M  39.997 g NaOH / 100 ml Barnstead Nanopure H2O 
Dissolve NaOH in 100 ml H2O overnight, on ice while being stirred. 
Sodium Dodecyl Sulfate (SDS) – 10 % 10 g SDS / 100 ml nanopure H2O 
Triethanolamine (TEOA) – 0.3 M, pH 
7.4 
2.24 g 99% TEOA / 50 ml Barnstead Nanopure H2O 
Highly viscous ∴ must dilute in same container it is weighed out in. 
pH to 7.4 with HCl 
Tris/borate/EDTA (TBE) 
electrophoresis buffer 10X, pH 8.3 
108 g Trisma® base (890 mM), 55 g Boric acid (890 mM), 40 ml 0.5 M EDTA  
(pH 8.0) (0.02M) / 1 L Nanopure H2O, Sterilise by autoclave 
TRIS  1.2114 g Trisma®-Base (100 mM) / 100 ml Barnstead Nanopure H2O 
Do not pH 
TRIS-Cl –10 mM, pH 7.3 10 ml 100 mM Tris / 100 ml Nanopure H2O (v/v), pH with 6 N & 1 N  HCl to 7.3  
Trypan Blue 0.4% (m/v) in PBS. Arrived pre-prepared 
Trypsin /  EDTA 100 ml Trypsin / EDTA was made up to 1 L with either Barnstead Nanopure 
H2O or 1X PBS pH 7.4 depending on how it arrived 
Stored at -20°C in 12 ml aliquots. 
  
Table A2.2: Preparation for collagen hydrogels – components and recipes 
Bovine collagen Arrived in liquid form from the supplier therefore no preparation required. Store 
at 4°C.  
Rat tail collagen  Arrived lyophilised and was resuspended sterile 0.2% acetic acid (v/v) overnight at 
room temperature. Special attention was made to not agitate the bottle. Once 
resuspended collagen was store at 4°C. 
Acetic acid – 0.2% (v/v) 100.3 µl 99.7% acetic acid in 50 ml Barnstead Nanopure H2O 
Sterilise using 0.2 µm syringe filters 




DMEM - 10X,  pH 7.4 13.4 g DMEM powder / 100 ml Barnstead Nanopure H2O 
pH to 0.1-0.3 pH units below 7.4 with 1 N HCl or 1 N NaOH.  
  
DMEM - 100ml, 1X,  pH 10,  
 
10 ml 10X DMEM (pH 7.4), 10 ml NaHCO3 (23 mg / ml) 
pH to 10 with 1 N NaOH  
80 ml nanopure H2O  
NaHCO3 (23 mg / ml) 0.23 g NaHCO3 / 10 ml nanopure H2O 
NaOH (0.36 M) 144 µl 10 M NaOH 
3856 µl nanopure H2O 
 All reagents (except the collagen) were individually sterilised using separate 0.2 
µm syringe filters. 10X DMEM and 1X DMEM were stored as 1 ml aliquots at -20°C. 
The NaCHO3 and NaOH were stored at 4°C.  
 
Table A2.3: Recipe and components of 6.68 mh/ml Proteinase K for PEG hydrogel digestion 
 Volume 
Proteinase K 10 mg / ml stock 100.2 µl 
CaCl2 100 mM 10.02 µl 
10 mM Tris pH  39.78 µl 
*Proteinase K is activated in the presence of 1-5 mM Ca2+. 
 
Table A2.4: Table according to which PEG hydrogels were digested 
 Volume 
Hydrogel 20 µl 
Proteinase K 6.68 mg/ml 10 µl 























A3: Siliconized surfaces 
 
Different surfaces were siliconized using Sigmacote®. Between 500 µl and 3 ml of Sigmacote® was used to cover the 
surface of a petri dish or tissue culture plate being siliconized. After 1 minute the Sigmacoate® was removed and the 
surface allowed to dry overnight. The surface was then rinsed 2X with DEPC treated H2O and allowed to dry. Once dry 
the surface was polished with a lint free cloth. To remove any dust or in the case of tissue culture plates which had 
been score, a high pressure air hose was to remove any excess plastic or dust. Plate or petri dish was then sterillsed 
with ethylene oxide. 
 
 
Figure A3.1: 24 well plate preparation. The plates were prepared in the laminar flow hood as much as possible to limit contamination.  1. Sterile 
24 well plate. 2. Specially made surgical punch was used to score the centre of each well. 3. Wells were siliconised with Sigmacote®. 4. A lint free 
cloth was used to polish wells. 5. High pressure air hose was used to get rid of any plastic shards. 6. Plate was sterilised by gas (ethylene oxide). 
Appendices   
111 
 
A4: Size and Zeta Potential reports 
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A5: Incubation of PEG monomer with 20:1 PEI/siRNA nanoparticles 
 
 
Figure A5.1: Incubation of PEG monomer with 20:1 PEI/siRNA nanoparticles. The PEG monomer was incubated for 30 minutes 
with the nanoparticles prior to transfection.  
 
 
